{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 974426, "items": [{"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T03:44:30Z", "timestamp": 1574307870967}, "reference-count": 35, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2009, 6, 21]], "date-time": "2009-06-21T00:00:00Z", "timestamp": 1245542400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Angiogenesis"], "published-print": {"date-parts": [[2009, 9]]}, "DOI": "10.1007/s10456-009-9151-7", "type": "journal-article", "created": {"date-parts": [[2009, 6, 20]], "date-time": "2009-06-20T08:06:16Z", "timestamp": 1245485176000}, "page": "287-296", "source": "Crossref", "is-referenced-by-count": 3, "title": ["A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo"], "prefix": "10.1007", "volume": "12", "author": [{"given": "Kenneth R.", "family": "LaMontagne", "sequence": "first", "affiliation": []}, {"given": "Jeannene", "family": "Butler", "sequence": "additional", "affiliation": []}, {"given": "Virna B.", "family": "Borowski", "sequence": "additional", "affiliation": []}, {"given": "Angel R.", "family": "Fuentes-Pesquera", "sequence": "additional", "affiliation": []}, {"given": "Jonathan M.", "family": "Blevitt", "sequence": "additional", "affiliation": []}, {"given": "Shenlin", "family": "Huang", "sequence": "additional", "affiliation": []}, {"given": "Ronghua", "family": "Li", "sequence": "additional", "affiliation": []}, {"given": "Peter J.", "family": "Connolly", "sequence": "additional", "affiliation": []}, {"given": "Lee M.", "family": "Greenberger", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 6, 21]]}, "reference": [{"key": "9151_CR1", "doi-asserted-by": "crossref", "first-page": "27", "DOI": "10.1038/nm0195-27", "volume": "1", "author": "J Folkman", "year": "1995", "unstructured": "Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27\u201331", "journal-title": "Nat Med"}, {"key": "9151_CR2", "doi-asserted-by": "crossref", "first-page": "249", "DOI": "10.1038/35025220", "volume": "407", "author": "P Carmeliet", "year": "2000", "unstructured": "Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249\u2013257", "journal-title": "Nature"}, {"key": "9151_CR3", "doi-asserted-by": "crossref", "first-page": "669", "DOI": "10.1038/nm0603-669", "volume": "9", "author": "N Ferrara", "year": "2003", "unstructured": "Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676", "journal-title": "Nat Med"}, {"key": "9151_CR4", "first-page": "5629", "volume": "46", "author": "DR Senger", "year": "1986", "unstructured": "Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629\u20135632", "journal-title": "Cancer Res"}, {"key": "9151_CR5", "doi-asserted-by": "crossref", "first-page": "851", "DOI": "10.1016/0006-291X(89)92678-8", "volume": "161", "author": "N Ferrara", "year": "1989", "unstructured": "Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851\u2013858", "journal-title": "Biochem Biophys Res Commun"}, {"key": "9151_CR6", "first-page": "10931", "volume": "267", "author": "J Folkman", "year": "1992", "unstructured": "Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931\u201310934", "journal-title": "J Biol Chem"}, {"key": "9151_CR7", "doi-asserted-by": "crossref", "first-page": "527", "DOI": "10.1007/s001099900019", "volume": "77", "author": "N Ferrara", "year": "1999", "unstructured": "Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527\u2013543", "journal-title": "J Mol Med"}, {"key": "9151_CR8", "doi-asserted-by": "crossref", "first-page": "835", "DOI": "10.1016/0092-8674(93)90573-9", "volume": "72", "author": "B Millauer", "year": "1993", "unstructured": "Millauer B, Wizigmann-Voos S, Schnurch H et al (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835\u2013846", "journal-title": "Cell"}, {"key": "9151_CR9", "doi-asserted-by": "crossref", "first-page": "721", "DOI": "10.1006/bbrc.1995.2832", "volume": "217", "author": "B Liu", "year": "1995", "unstructured": "Liu B, Earl HM, Baban D et al (1995) Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 217:721\u2013727", "journal-title": "Biochem Biophys Res Commun"}, {"key": "9151_CR10", "doi-asserted-by": "crossref", "first-page": "409", "DOI": "10.1097/00000658-197203000-00014", "volume": "175", "author": "J Folkman", "year": "1972", "unstructured": "Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409\u2013416", "journal-title": "Ann Surg"}, {"key": "9151_CR11", "first-page": "3964", "volume": "55", "author": "Y Takahashi", "year": "1995", "unstructured": "Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964\u20133968", "journal-title": "Cancer Res"}, {"key": "9151_CR12", "first-page": "4819", "volume": "60", "author": "J Drevs", "year": "2000", "unstructured": "Drevs J, Hofmann I, Hugenschmidt H et al (2000) Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819\u20134824", "journal-title": "Cancer Res"}, {"key": "9151_CR13", "doi-asserted-by": "crossref", "first-page": "635", "DOI": "10.1124/mol.104.000638", "volume": "66", "author": "S Emanuel", "year": "2004", "unstructured": "Emanuel S, Gruninger RH, Fuentes-Pesquera A et al (2004) A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol Pharmacol 66:635\u2013647", "journal-title": "Mol Pharmacol"}, {"key": "9151_CR14", "first-page": "99", "volume": "59", "author": "TA Fong", "year": "1999", "unstructured": "Fong TA, Shawver LK, Sun L et al (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99\u2013106", "journal-title": "Cancer Res"}, {"key": "9151_CR15", "first-page": "970", "volume": "60", "author": "SR Wedge", "year": "2000", "unstructured": "Wedge SR, Ogilvie DJ, Dukes M et al (2000) ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60:970\u2013975", "journal-title": "Cancer Res"}, {"key": "9151_CR16", "doi-asserted-by": "crossref", "first-page": "7099", "DOI": "10.1158/0008-5472.CAN-04-1443", "volume": "64", "author": "SM Wilhelm", "year": "2004", "unstructured": "Wilhelm SM, Carter C, Tang L et al (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109", "journal-title": "Cancer Res"}, {"key": "9151_CR17", "doi-asserted-by": "crossref", "first-page": "391", "DOI": "10.1038/nrd2541", "volume": "7", "author": "DM Goldstein", "year": "2008", "unstructured": "Goldstein DM, Gray NS, Zarrinkar PP (2008) High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 7:391\u2013397", "journal-title": "Nat Rev Drug Discov"}, {"key": "9151_CR18", "doi-asserted-by": "crossref", "first-page": "221", "DOI": "10.1158/0008-5472.CAN-05-2001", "volume": "66", "author": "K LaMontagne", "year": "2006", "unstructured": "LaMontagne K, Littlewood-Evans A, Schnell C et al (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66:221\u2013231", "journal-title": "Cancer Res"}, {"key": "9151_CR19", "first-page": "1625", "volume": "37", "author": "BM Kenyon", "year": "1996", "unstructured": "Kenyon BM, Voest EE, Chen CC et al (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37:1625\u20131632", "journal-title": "Invest Ophthalmol Vis Sci"}, {"key": "9151_CR20", "first-page": "4009", "volume": "63", "author": "AJ Schueneman", "year": "2003", "unstructured": "Schueneman AJ, Himmelfarb E, Geng L et al (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63:4009\u20134016", "journal-title": "Cancer Res"}, {"key": "9151_CR21", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.0.CO;2-O", "volume": "277", "author": "K Yang", "year": "1997", "unstructured": "Yang K, Edelmann W, Fan K et al (1997) A mouse model of human familial adenomatous polyposis. J Exp Zool 277:245\u2013254", "journal-title": "J Exp Zool"}, {"key": "9151_CR22", "doi-asserted-by": "crossref", "first-page": "713", "DOI": "10.1634/theoncologist.12-6-713", "volume": "12", "author": "MH Cohen", "year": "2007", "unstructured": "Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Bevacizumab) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713\u2013718", "journal-title": "Oncologist"}, {"key": "9151_CR23", "doi-asserted-by": "crossref", "first-page": "3765", "DOI": "10.1158/1078-0432.CCR-06-2844", "volume": "13", "author": "MN Stein", "year": "2007", "unstructured": "Stein MN, Flaherty KT (2007) CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 13:3765\u20133770", "journal-title": "Clin Cancer Res"}, {"key": "9151_CR24", "doi-asserted-by": "crossref", "first-page": "3222", "DOI": "10.1074/jbc.M002016200", "volume": "276", "author": "H Gille", "year": "2001", "unstructured": "Gille H, Kowalski J, Li B et al (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276:3222\u20133230", "journal-title": "J Biol Chem"}, {"key": "9151_CR25", "doi-asserted-by": "crossref", "first-page": "363", "DOI": "10.1093/emboj/18.2.363", "volume": "18", "author": "M Meyer", "year": "1999", "unstructured": "Meyer M, Clauss M, Lepple-Wienhues A et al (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18:363\u2013374", "journal-title": "EMBO J"}, {"key": "9151_CR26", "doi-asserted-by": "crossref", "first-page": "32714", "DOI": "10.1074/jbc.M103130200", "volume": "276", "author": "H Zeng", "year": "2001", "unstructured": "Zeng H, Sanyal S, Mukhopadhyay D (2001) Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276:32714\u201332719", "journal-title": "J Biol Chem"}, {"key": "9151_CR27", "doi-asserted-by": "crossref", "first-page": "10661", "DOI": "10.1074/jbc.275.14.10661", "volume": "275", "author": "S Rousseau", "year": "2000", "unstructured": "Rousseau S, Houle F, Kotanides H et al (2000) Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 275:10661\u201310672", "journal-title": "J Biol Chem"}, {"key": "9151_CR28", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.1016/j.bbrc.2008.07.121", "volume": "375", "author": "R Roskoski Jr", "year": "2008", "unstructured": "Roskoski R Jr (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375:287\u2013291", "journal-title": "Biochem Biophys Res Commun"}, {"key": "9151_CR29", "doi-asserted-by": "crossref", "first-page": "2003", "DOI": "10.1016/j.cellsig.2007.05.013", "volume": "19", "author": "K Holmes", "year": "2007", "unstructured": "Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 19:2003\u20132012", "journal-title": "Cell Signal"}, {"key": "9151_CR30", "doi-asserted-by": "crossref", "first-page": "28", "DOI": "10.1038/nrc2559", "volume": "9", "author": "J Zhang", "year": "2009", "unstructured": "Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28\u201339", "journal-title": "Nat Rev Cancer"}, {"key": "9151_CR31", "first-page": "5090", "volume": "61", "author": "A Viloria-Petit", "year": "2001", "unstructured": "Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090\u20135101", "journal-title": "Cancer Res"}, {"key": "9151_CR32", "doi-asserted-by": "crossref", "first-page": "3609", "DOI": "10.1073/pnas.95.7.3609", "volume": "95", "author": "F Okada", "year": "1998", "unstructured": "Okada F, Rak JW, Croix BS et al (1998) Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95:3609\u20133614", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "9151_CR33", "doi-asserted-by": "crossref", "first-page": "30336", "DOI": "10.1074/jbc.273.46.30336", "volume": "273", "author": "HP Gerber", "year": "1998", "unstructured": "Gerber HP, McMurtrey A, Kowalski J et al (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3\u2032-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336\u201330343", "journal-title": "J Biol Chem"}, {"key": "9151_CR34", "doi-asserted-by": "crossref", "first-page": "576", "DOI": "10.1002/ijc.20012", "volume": "109", "author": "T Kitamura", "year": "2004", "unstructured": "Kitamura T, Itoh M, Noda T, Matsuura M, Wakabayashi K (2004) Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Int J Cancer 109:576\u2013580", "journal-title": "Int J Cancer"}, {"key": "9151_CR35", "doi-asserted-by": "crossref", "first-page": "2335", "DOI": "10.1056/NEJMoa032691", "volume": "350", "author": "H Hurwitz", "year": "2004", "unstructured": "Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342", "journal-title": "N Engl J Med"}], "container-title": ["Angiogenesis"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s10456-009-9151-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s10456-009-9151-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s10456-009-9151-7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 29]], "date-time": "2019-05-29T17:26:21Z", "timestamp": 1559150781000}, "score": 60.847885, "issued": {"date-parts": [[2009, 6, 21]]}, "references-count": 35, "journal-issue": {"published-print": {"date-parts": [[2009, 9]]}, "issue": "3"}, "alternative-id": ["9151"], "URL": "http://dx.doi.org/10.1007/s10456-009-9151-7", "relation": {"cites": []}, "ISSN": ["0969-6970", "1573-7209"], "issn-type": [{"value": "0969-6970", "type": "print"}, {"value": "1573-7209", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 18]], "date-time": "2019-12-18T03:25:47Z", "timestamp": 1576639547722}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Res"], "published-print": {"date-parts": [[2005, 5, 15]]}, "DOI": "10.1158/0008-5472.can-04-4409", "type": "journal-article", "created": {"date-parts": [[2005, 9, 15]], "date-time": "2005-09-15T21:37:49Z", "timestamp": 1126820269000}, "page": "4389-4400", "source": "Crossref", "is-referenced-by-count": 477, "title": ["AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer"], "prefix": "10.1158", "volume": "65", "author": [{"given": "Stephen R.", "family": "Wedge", "sequence": "first", "affiliation": []}, {"given": "Jane", "family": "Kendrew", "sequence": "additional", "affiliation": []}, {"given": "Laurent F.", "family": "Hennequin", "sequence": "additional", "affiliation": []}, {"given": "Paula J.", "family": "Valentine", "sequence": "additional", "affiliation": []}, {"given": "Simon T.", "family": "Barry", "sequence": "additional", "affiliation": []}, {"given": "Sandra R.", "family": "Brave", "sequence": "additional", "affiliation": []}, {"given": "Neil R.", "family": "Smith", "sequence": "additional", "affiliation": []}, {"given": "Neil H.", "family": "James", "sequence": "additional", "affiliation": []}, {"given": "Michael", "family": "Dukes", "sequence": "additional", "affiliation": []}, {"given": "Jon O.", "family": "Curwen", "sequence": "additional", "affiliation": []}, {"given": "Rosemary", "family": "Chester", "sequence": "additional", "affiliation": []}, {"given": "Janet A.", "family": "Jackson", "sequence": "additional", "affiliation": []}, {"given": "Sarah J.", "family": "Boffey", "sequence": "additional", "affiliation": []}, {"given": "Lyndsey L.", "family": "Kilburn", "sequence": "additional", "affiliation": []}, {"given": "Sharon", "family": "Barnett", "sequence": "additional", "affiliation": []}, {"given": "Graham H.P.", "family": "Richmond", "sequence": "additional", "affiliation": []}, {"given": "Peter F.", "family": "Wadsworth", "sequence": "additional", "affiliation": []}, {"given": "Mike", "family": "Walker", "sequence": "additional", "affiliation": []}, {"given": "Alison L.", "family": "Bigley", "sequence": "additional", "affiliation": []}, {"given": "Sian T.", "family": "Taylor", "sequence": "additional", "affiliation": []}, {"given": "Lee", "family": "Cooper", "sequence": "additional", "affiliation": []}, {"given": "Sarah", "family": "Beck", "sequence": "additional", "affiliation": []}, {"given": "Juliane M.", "family": "J\u00fcrgensmeier", "sequence": "additional", "affiliation": []}, {"given": "Donald J.", "family": "Ogilvie", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2005, 5, 16]]}, "container-title": ["Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.CAN-04-4409", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 7, 21]], "date-time": "2017-07-21T22:26:01Z", "timestamp": 1500675961000}, "score": 57.34974, "issued": {"date-parts": [[2005, 5, 15]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2005, 5, 16]]}, "published-print": {"date-parts": [[2005, 5, 15]]}, "issue": "10"}, "alternative-id": ["10.1158/0008-5472.CAN-04-4409"], "URL": "http://dx.doi.org/10.1158/0008-5472.can-04-4409", "ISSN": ["0008-5472", "1538-7445"], "issn-type": [{"value": "0008-5472", "type": "print"}, {"value": "1538-7445", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T05:32:21Z", "timestamp": 1574314341788}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "15", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2007, 8, 1]]}, "DOI": "10.1158/1078-0432.ccr-06-2636", "type": "journal-article", "created": {"date-parts": [[2007, 8, 1]], "date-time": "2007-08-01T18:19:18Z", "timestamp": 1185992358000}, "page": "4519-4527", "source": "Crossref", "is-referenced-by-count": 30, "title": ["The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model"], "prefix": "10.1158", "volume": "13", "author": [{"given": "F.", "family": "Gomez-Rivera", "sequence": "first", "affiliation": []}, {"given": "A. A.", "family": "Santillan-Gomez", "sequence": "additional", "affiliation": []}, {"given": "M. N.", "family": "Younes", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Kim", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Fooshee", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Zhao", "sequence": "additional", "affiliation": []}, {"given": "S. A.", "family": "Jasser", "sequence": "additional", "affiliation": []}, {"given": "J. N.", "family": "Myers", "sequence": "additional", "affiliation": []}], "member": "1086", "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-06-2636", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T03:44:02Z", "timestamp": 1482464642000}, "score": 53.746933, "issued": {"date-parts": [[2007, 8, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2007, 8, 1]]}, "issue": "15"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-06-2636", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T08:43:42Z", "timestamp": 1574325822735}, "publisher-location": "Hoboken, NJ, USA", "reference-count": 0, "publisher": "John Wiley & Sons, Inc.", "isbn-type": [{"value": "9780470278291", "type": "print"}, {"value": "9780470524961", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1002/9780470524961.ch6", "type": "book-chapter", "created": {"date-parts": [[2009, 9, 28]], "date-time": "2009-09-28T14:16:27Z", "timestamp": 1254147387000}, "page": "131-166", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor"], "prefix": "10.1002", "author": [{"given": "Rajeev S.", "family": "Bhide", "sequence": "first", "affiliation": []}, {"given": "Joseph", "family": "Fargnoli", "sequence": "additional", "affiliation": []}], "member": "311", "container-title": ["Kinase Inhibitor Drugs"], "deposited": {"date-parts": [[2009, 9, 28]], "date-time": "2009-09-28T14:16:36Z", "timestamp": 1254147396000}, "score": 52.332428, "issued": {"date-parts": [[null]]}, "ISBN": ["9780470524961", "9780470278291"], "references-count": 0, "URL": "http://dx.doi.org/10.1002/9780470524961.ch6"}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T06:35:38Z", "timestamp": 1574145338904}, "reference-count": 35, "publisher": "Wiley", "issue": "6", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 4657, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2002, 12]]}, "DOI": "10.1038/sj.mn.7800164", "type": "journal-article", "created": {"date-parts": [[2002, 12, 13]], "date-time": "2002-12-13T11:57:05Z", "timestamp": 1039780625000}, "page": "513-522", "source": "Crossref", "is-referenced-by-count": 50, "title": ["ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity"], "prefix": "10.1111", "volume": "9", "author": [{"given": "C.E.", "family": "WHITTLES", "sequence": "first", "affiliation": []}, {"given": "T.M.", "family": "POCOCK", "sequence": "additional", "affiliation": []}, {"given": "S.R.", "family": "WEDGE", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "KENDREW", "sequence": "additional", "affiliation": []}, {"given": "L.F.", "family": "HENNEQUIN", "sequence": "additional", "affiliation": []}, {"given": "S.J.", "family": "HARPER", "sequence": "additional", "affiliation": []}, {"given": "D.O.", "family": "BATES", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "10.1038/sj.mn.7800164-BIB1", "doi-asserted-by": "crossref", "first-page": "548", "DOI": "10.1073/pnas.95.2.548", "article-title": "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)", "volume": "95", "author": "Achen", "year": "1998", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1038/sj.mn.7800164-BIB2", "author": "Basser", "year": "2001", "volume-title": "Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology."}, {"key": "10.1038/sj.mn.7800164-BIB3", "first-page": "H2520", "article-title": "Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels", "volume": "271", "author": "Bates", "year": "1996", "journal-title": "Am J Physiol"}, {"key": "10.1038/sj.mn.7800164-BIB4", "doi-asserted-by": "crossref", "first-page": "83", "DOI": "10.1038/sj.mn.7300054", "article-title": "Vascular endothelial growth factor and microvascular permeability", "volume": "6", "author": "Bates", "year": "1999", "journal-title": "Microcirculation"}, {"key": "10.1038/sj.mn.7800164-BIB5", "author": "Curry", "first-page": "1", "year": "1983", "volume-title": "Cardiovascular Physiology. Techniques in the Life Sciences."}, {"key": "10.1038/sj.mn.7800164-BIB6", "doi-asserted-by": "crossref", "first-page": "989", "DOI": "10.1126/science.1312256", "article-title": "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor", "volume": "255", "author": "Vries", "year": "1992", "journal-title": "Science"}, {"key": "10.1038/sj.mn.7800164-BIB7", "first-page": "4819", "article-title": "Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model", "volume": "60", "author": "Drevs", "year": "2000", "journal-title": "Cancer Res"}, {"key": "10.1038/sj.mn.7800164-BIB8", "doi-asserted-by": "crossref", "first-page": "699", "DOI": "10.1006/dbio.1995.1180", "article-title": "Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo", "volume": "169", "author": "Flamme", "year": "1995", "journal-title": "Dev Biol"}, {"key": "10.1038/sj.mn.7800164-BIB9", "doi-asserted-by": "crossref", "first-page": "843", "DOI": "10.1200/JCO.2001.19.3.843", "article-title": "Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer", "volume": "19", "author": "Gordon", "year": "2001", "journal-title": "J Clin Oncol"}, {"key": "10.1038/sj.mn.7800164-BIB10", "doi-asserted-by": "crossref", "first-page": "6729", "DOI": "10.1074/jbc.270.12.6729", "article-title": "Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation", "volume": "270", "author": "Guo", "year": "1995", "journal-title": "J Biol Chem"}, {"key": "10.1038/sj.mn.7800164-BIB11", "first-page": "R468", "article-title": "Seasonal variations of capillary hydraulic conductivity and volume status", "volume": "268", "author": "Hargrave", "year": "1995", "journal-title": "Am J Physiol"}, {"key": "10.1038/sj.mn.7800164-BIB12", "doi-asserted-by": "crossref", "first-page": "5369", "DOI": "10.1021/jm990345w", "article-title": "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors", "volume": "42", "author": "Hennequin", "year": "1999", "journal-title": "J Med Chem"}, {"key": "10.1038/sj.mn.7800164-BIB13", "doi-asserted-by": "crossref", "first-page": "176", "DOI": "10.1159/000051044", "article-title": "Differential effects of vascular endothelial growth factor-C and placental growth factor-1 on the hydraulic conductivity of frog mesenteric capillaries", "volume": "38", "author": "Hillman", "year": "2001", "journal-title": "J Vasc Res"}, {"key": "10.1038/sj.mn.7800164-BIB14", "first-page": "290", "article-title": "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases", "volume": "15", "author": "Joukov", "year": "1996", "journal-title": "EMBO J"}, {"key": "10.1038/sj.mn.7800164-BIB15", "doi-asserted-by": "crossref", "first-page": "326", "DOI": "10.1006/bbrc.1994.1705", "article-title": "Specificity of vascular endothelial cell growth factor receptor ligand binding domains", "volume": "201", "author": "Kendall", "year": "1994", "journal-title": "Biochem Biophys Res Commun"}, {"key": "10.1038/sj.mn.7800164-BIB16", "doi-asserted-by": "crossref", "first-page": "324", "DOI": "10.1006/bbrc.1996.1355", "article-title": "Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its het-erodimerization with KDR", "volume": "226", "author": "Kendall", "year": "1996", "journal-title": "Biochem Biophys Res Commun"}, {"key": "10.1038/sj.mn.7800164-BIB17", "first-page": "H586", "article-title": "Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries", "volume": "265", "author": "Ku", "year": "1993", "journal-title": "Am J Physiol"}, {"key": "10.1038/sj.mn.7800164-BIB18", "author": "Lohmann", "year": "1999", "volume-title": "United States Patent Office"}, {"key": "10.1038/sj.mn.7800164-BIB19", "doi-asserted-by": "crossref", "first-page": "703", "DOI": "10.1152/physrev.1999.79.3.703", "article-title": "Microvascular permeability", "volume": "79", "author": "Michel", "year": "1999", "journal-title": "Physiol Rev"}, {"key": "10.1038/sj.mn.7800164-BIB20", "first-page": "283", "article-title": "A development of the Landis technique for measuring the filtration coefficient of individual capillaries in the frog mesentery", "volume": "59", "author": "Michel", "year": "1974", "journal-title": "Q J Exp Phys Cog Med Sci"}, {"key": "10.1038/sj.mn.7800164-BIB21", "doi-asserted-by": "crossref", "first-page": "528", "DOI": "10.1016/S0958-1669(99)00024-5", "article-title": "Current biology of VEGF-B and VEGF-C", "volume": "10", "author": "Olofsson", "year": "1999", "journal-title": "Curr Opin Biotechnol"}, {"key": "10.1038/sj.mn.7800164-BIB22", "doi-asserted-by": "crossref", "first-page": "2576", "DOI": "10.1073/pnas.93.6.2576", "article-title": "Vascular endothelial growth factor B, a novel growth factor for endothelial cells", "volume": "93", "author": "Olofsson", "year": "1996", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1038/sj.mn.7800164-BIB23", "first-page": "25646", "article-title": "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR", "volume": "269", "author": "Park", "year": "1994", "journal-title": "J Biol Chem"}, {"key": "10.1038/sj.mn.7800164-BIB24", "doi-asserted-by": "crossref", "first-page": "479", "DOI": "10.1111/j.1469-7793.2001.00479.x", "article-title": "In vivo mechanisms of vascular endothelial growth factor-mediated increased hydraulic conductivity of Rana capillaries", "volume": "534", "author": "Pocock", "year": "2001", "journal-title": "J Physiol (Lond)"}, {"key": "10.1038/sj.mn.7800164-BIB25", "doi-asserted-by": "crossref", "first-page": "7533", "DOI": "10.1073/pnas.90.16.7533", "article-title": "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium", "volume": "90", "author": "Quinn", "year": "1993", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1038/sj.mn.7800164-BIB26", "first-page": "135", "article-title": "A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF", "volume": "10", "author": "Seetharam", "year": "1995", "journal-title": "Oncogene"}, {"key": "10.1038/sj.mn.7800164-BIB27", "first-page": "1774", "article-title": "Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor", "volume": "50", "author": "Senger", "year": "1990", "journal-title": "Cancer Res"}, {"key": "10.1038/sj.mn.7800164-BIB28", "doi-asserted-by": "crossref", "first-page": "34884", "DOI": "10.1074/jbc.274.49.34884", "article-title": "A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability", "volume": "274", "author": "Stacker", "year": "1999", "journal-title": "J Biol Chem"}, {"key": "10.1038/sj.mn.7800164-BIB29", "first-page": "26988", "article-title": "Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor", "volume": "269", "author": "Waltenberger", "year": "1994", "journal-title": "J Biol Chem"}, {"key": "10.1038/sj.mn.7800164-BIB30", "doi-asserted-by": "crossref", "first-page": "501", "DOI": "10.1042/bj3470501", "article-title": "The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells", "volume": "347", "author": "Warner", "year": "2000", "journal-title": "Biochem J"}, {"key": "10.1038/sj.mn.7800164-BIB31", "first-page": "970", "article-title": "ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy", "volume": "60", "author": "Wedge", "year": "2000", "journal-title": "Cancer Res"}, {"key": "10.1038/sj.mn.7800164-BIB32", "first-page": "2178", "article-title": "PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration", "volume": "60", "author": "Wood", "year": "2000", "journal-title": "Cancer Res"}, {"key": "10.1038/sj.mn.7800164-BIB33", "first-page": "H2735", "article-title": "VEGF induces NO-dependent hyperpermeability in coronary venules", "volume": "271", "author": "Wu", "year": "1996", "journal-title": "Am J Physiol"}, {"key": "10.1038/sj.mn.7800164-BIB34", "first-page": "445", "article-title": "Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases", "volume": "16", "author": "Xu", "year": "2000", "journal-title": "Int J Oncol"}, {"key": "10.1038/sj.mn.7800164-BIB35", "first-page": "957", "article-title": "Treatment for malignant pleural effusion of human lung adeno-carcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation", "volume": "6", "author": "Yano", "year": "2000", "journal-title": "Clin Cancer Res"}], "container-title": ["Microcirculation"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1038%2Fsj.mn.7800164", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 1, 21]], "date-time": "2018-01-21T19:45:04Z", "timestamp": 1516563904000}, "score": 52.006428, "issued": {"date-parts": [[2002, 12]]}, "references-count": 35, "journal-issue": {"published-print": {"date-parts": [[2002, 12]]}, "issue": "6"}, "URL": "http://dx.doi.org/10.1038/sj.mn.7800164", "relation": {"cites": []}, "ISSN": ["1073-9688", "1549-8719"], "issn-type": [{"value": "1073-9688", "type": "print"}, {"value": "1549-8719", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T20:59:48Z", "timestamp": 1574456388672}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "8", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Research"], "published-print": {"date-parts": [[2012, 4, 15]]}, "DOI": "10.1158/0008-5472.can-11-3034", "type": "journal-article", "created": {"date-parts": [[2012, 2, 28]], "date-time": "2012-02-28T04:35:06Z", "timestamp": 1330403706000}, "page": "2045-2056", "source": "Crossref", "is-referenced-by-count": 231, "title": ["AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family"], "prefix": "10.1158", "volume": "72", "author": [{"given": "P. R.", "family": "Gavine", "sequence": "first", "affiliation": []}, {"given": "L.", "family": "Mooney", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Kilgour", "sequence": "additional", "affiliation": []}, {"given": "A. P.", "family": "Thomas", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Al-Kadhimi", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Beck", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Rooney", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Coleman", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Baker", "sequence": "additional", "affiliation": []}, {"given": "M. J.", "family": "Mellor", "sequence": "additional", "affiliation": []}, {"given": "A. N.", "family": "Brooks", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Klinowska", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2012, 2, 27]]}, "container-title": ["Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.CAN-11-3034", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T13:03:05Z", "timestamp": 1482498185000}, "score": 51.732265, "issued": {"date-parts": [[2012, 2, 27]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2012, 4, 16]]}, "published-print": {"date-parts": [[2012, 4, 15]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1158/0008-5472.can-11-3034", "ISSN": ["0008-5472", "1538-7445"], "issn-type": [{"value": "0008-5472", "type": "print"}, {"value": "1538-7445", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:59:26Z", "timestamp": 1575305966475}, "reference-count": 21, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2005, 12, 1]], "date-time": "2005-12-01T00:00:00Z", "timestamp": 1133395200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Breast Cancer"], "published-print": {"date-parts": [[2005, 12]]}, "DOI": "10.3816/cbc.2005.n.052", "type": "journal-article", "created": {"date-parts": [[2008, 9, 11]], "date-time": "2008-09-11T01:07:34Z", "timestamp": 1221095254000}, "page": "460-463", "source": "Crossref", "is-referenced-by-count": 3, "title": ["A Pilot Study to Evaluate the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor AZD2171 and Chemotherapy in Locally Advanced and Inflammatory Breast Cancer"], "prefix": "10.3816", "volume": "6", "author": [{"given": "Neelima", "family": "Denduluri", "sequence": "first", "affiliation": []}, {"given": "Antoinette R.", "family": "Tan", "sequence": "additional", "affiliation": []}, {"given": "Janice", "family": "Walshe", "sequence": "additional", "affiliation": []}, {"given": "Arlene", "family": "Berman", "sequence": "additional", "affiliation": []}, {"given": "Sherry X.", "family": "Yang", "sequence": "additional", "affiliation": []}, {"given": "Catherine K.", "family": "Chow", "sequence": "additional", "affiliation": []}, {"given": "Sandra M.", "family": "Swain", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Breast Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1526820911704669?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1526820911704669?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 13]], "date-time": "2019-05-13T23:00:08Z", "timestamp": 1557788408000}, "score": 51.56889, "issued": {"date-parts": [[2005, 12]]}, "references-count": 21, "journal-issue": {"published-print": {"date-parts": [[2005, 12]]}, "issue": "5"}, "alternative-id": ["S1526820911704669"], "URL": "http://dx.doi.org/10.3816/cbc.2005.n.052", "ISSN": ["1526-8209"], "issn-type": [{"value": "1526-8209", "type": "print"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T15:18:17Z", "timestamp": 1575213497650}, "reference-count": 0, "publisher": "Cognizant, LLC", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["oncol res"], "published-print": {"date-parts": [[2006, 1, 1]]}, "DOI": "10.3727/000000006783981260", "type": "journal-article", "created": {"date-parts": [[2017, 12, 22]], "date-time": "2017-12-22T15:27:56Z", "timestamp": 1513956476000}, "page": "15-26", "source": "Crossref", "is-referenced-by-count": 27, "title": ["ZD6474, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, Inhibits Growth of Experimental Lung Metastasis and Production of Malignant Pleural Effusions in a Non-Small Cell Lung Cancer Model"], "prefix": "10.3727", "volume": "16", "author": [{"given": "Yuka", "family": "Matsumori", "sequence": "first", "affiliation": [{"name": "Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, 3-18-15 Kuramoto-cho, Tokushima, Japan"}]}, {"given": "Seiji", "family": "Yano", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, 3-18-15 Kuramoto-cho, Tokushima, Japan"}]}, {"given": "Hisatsugu", "family": "Goto", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, 3-18-15 Kuramoto-cho, Tokushima, Japan"}]}, {"given": "Emiko", "family": "Nakataki", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, 3-18-15 Kuramoto-cho, Tokushima, Japan"}]}, {"given": "Stephen R.", "family": "Wedge", "sequence": "additional", "affiliation": [{"name": "AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK"}]}, {"given": "Anderson J.", "family": "Ryan", "sequence": "additional", "affiliation": [{"name": "AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK"}]}, {"given": "Saburo", "family": "Sone", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, 3-18-15 Kuramoto-cho, Tokushima, Japan"}]}], "member": "2029", "container-title": ["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"], "language": "en", "link": [{"URL": "http://www.ingentaconnect.com/content/cog/or/2006/00000016/00000001/art00002", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 12, 22]], "date-time": "2017-12-22T15:28:00Z", "timestamp": 1513956480000}, "score": 50.841663, "issued": {"date-parts": [[2006, 1, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2006, 1, 1]]}, "issue": "1"}, "alternative-id": ["0965-0407(20060101)16:1L.15;1-"], "URL": "http://dx.doi.org/10.3727/000000006783981260", "ISSN": ["0965-0407"], "issn-type": [{"value": "0965-0407", "type": "print"}], "subject": ["Cancer Research", "Oncology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T18:12:32Z", "timestamp": 1574273552519}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Molecular Cancer Therapeutics"], "DOI": "10.1158/1535-7163.mct-06-0508", "type": "journal-article", "created": {"date-parts": [[2007, 2, 16]], "date-time": "2007-02-16T18:31:14Z", "timestamp": 1171650674000}, "page": "599-606", "source": "Crossref", "is-referenced-by-count": 36, "title": ["Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit"], "prefix": "10.1158", "volume": "6", "author": [{"given": "K. J.", "family": "Williams", "sequence": "first", "affiliation": []}, {"given": "B. A.", "family": "Telfer", "sequence": "additional", "affiliation": []}, {"given": "A. M.", "family": "Shannon", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Babur", "sequence": "additional", "affiliation": []}, {"given": "I. J.", "family": "Stratford", "sequence": "additional", "affiliation": []}, {"given": "S. R.", "family": "Wedge", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2007, 2, 1]]}, "container-title": ["Molecular Cancer Therapeutics"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1535-7163.MCT-06-0508", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 22]], "date-time": "2016-12-22T23:42:51Z", "timestamp": 1482450171000}, "score": 50.641273, "issued": {"date-parts": [[2007, 2, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2007, 2, 1]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1158/1535-7163.mct-06-0508", "ISSN": ["1535-7163", "1538-8514"], "issn-type": [{"value": "1535-7163", "type": "print"}, {"value": "1538-8514", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T07:34:18Z", "timestamp": 1574148858091}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "8", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2004, 9, 1]], "date-time": "2004-09-01T00:00:00Z", "timestamp": 1093996800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2004, 9]]}, "DOI": "10.1016/s1359-6349(04)80173-3", "type": "journal-article", "created": {"date-parts": [[2004, 11, 18]], "date-time": "2004-11-18T06:37:36Z", "timestamp": 1100759856000}, "page": "52", "source": "Crossref", "is-referenced-by-count": 1, "title": ["165 AZD2171, a potent VEGF receptor tyrosine kinase inhibitor, combined with mechanistically distinct antitumor therapies in vivo"], "prefix": "10.1016", "volume": "2", "author": [{"given": "S.", "family": "Wedge", "sequence": "first", "affiliation": []}, {"given": "J.", "family": "Kendrew", "sequence": "additional", "affiliation": []}, {"given": "P.J.", "family": "Valentine", "sequence": "additional", "affiliation": []}, {"given": "S.R.", "family": "Brave", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Barnett", "sequence": "additional", "affiliation": []}, {"given": "J.M.", "family": "Jurgensmeier", "sequence": "additional", "affiliation": []}, {"given": "L.F.", "family": "Hennequin", "sequence": "additional", "affiliation": []}, {"given": "D.J.", "family": "Ogilvie", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634904801733?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634904801733?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 1]], "date-time": "2019-02-01T23:58:39Z", "timestamp": 1549065519000}, "score": 49.274906, "issued": {"date-parts": [[2004, 9]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2004, 9]]}, "issue": "8"}, "alternative-id": ["S1359634904801733"], "URL": "http://dx.doi.org/10.1016/s1359-6349(04)80173-3", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T22:23:43Z", "timestamp": 1574375023952}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Research"], "published-print": {"date-parts": [[2008, 6, 15]]}, "DOI": "10.1158/0008-5472.can-07-5809", "type": "journal-article", "created": {"date-parts": [[2008, 6, 16]], "date-time": "2008-06-16T17:52:54Z", "timestamp": 1213638774000}, "page": "4754-4762", "source": "Crossref", "is-referenced-by-count": 78, "title": ["The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis"], "prefix": "10.1158", "volume": "68", "author": [{"given": "C. A.", "family": "Heckman", "sequence": "first", "affiliation": []}, {"given": "T.", "family": "Holopainen", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Wirzenius", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Keskitalo", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Jeltsch", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Yla-Herttuala", "sequence": "additional", "affiliation": []}, {"given": "S. R.", "family": "Wedge", "sequence": "additional", "affiliation": []}, {"given": "J. M.", "family": "Jurgensmeier", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Alitalo", "sequence": "additional", "affiliation": []}], "member": "1086", "container-title": ["Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.CAN-07-5809", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T05:31:28Z", "timestamp": 1482471088000}, "score": 48.568443, "issued": {"date-parts": [[2008, 6, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 6, 15]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1158/0008-5472.can-07-5809", "ISSN": ["0008-5472", "1538-7445"], "issn-type": [{"value": "0008-5472", "type": "print"}, {"value": "1538-7445", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T11:14:28Z", "timestamp": 1574248468028}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "23", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Research"], "DOI": "10.1158/0008-5472.can-06-2414", "type": "journal-article", "created": {"date-parts": [[2006, 12, 4]], "date-time": "2006-12-04T17:52:48Z", "timestamp": 1165254768000}, "page": "11409-11415", "source": "Crossref", "is-referenced-by-count": 36, "title": ["Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer"], "prefix": "10.1158", "volume": "66", "author": [{"given": "C.", "family": "Cao", "sequence": "first", "affiliation": []}, {"given": "J. M.", "family": "Albert", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Geng", "sequence": "additional", "affiliation": []}, {"given": "P. S.", "family": "Ivy", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Sandler", "sequence": "additional", "affiliation": []}, {"given": "D. H.", "family": "Johnson", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Lu", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2006, 11, 17]]}, "container-title": ["Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.CAN-06-2414", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T14:46:10Z", "timestamp": 1482504370000}, "score": 47.62185, "issued": {"date-parts": [[2006, 11, 17]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2006, 11, 17]]}, "issue": "23"}, "URL": "http://dx.doi.org/10.1158/0008-5472.can-06-2414", "ISSN": ["0008-5472", "1538-7445"], "issn-type": [{"value": "0008-5472", "type": "print"}, {"value": "1538-7445", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T01:44:28Z", "timestamp": 1574732668948}, "reference-count": 0, "publisher": "Canadian Urological Association Journal", "issue": "11-12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["CUAJ"], "abstract": "<jats:p>Targeted therapy for metastatic renal cell carcinoma (mRCC) was introduced a decade ago, and since then a number of therapeutic options have been developed. Vascular endothelial growth factor targeted therapy is the widely accepted first-line option for mRCC. After progression, treatment in the second-line setting has typically been with either axitinib or everolimus. However, with the advent of several new agents demonstrating efficacy in the second-line setting, including nivolumab, cabozantinib, and the combination of lenvatinib and everolimus, the treatment paradigm has shifted toward these novel therapies with improved patient outcomes.</jats:p>", "DOI": "10.5489/cuaj.4292", "type": "journal-article", "created": {"date-parts": [[2017, 1, 6]], "date-time": "2017-01-06T13:21:21Z", "timestamp": 1483708881000}, "page": "242", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors"], "prefix": "10.5489", "volume": "10", "author": [{"given": "Naveen S.", "family": "Basappa", "sequence": "first", "affiliation": []}], "member": "3456", "published-online": {"date-parts": [[2016, 12, 15]]}, "container-title": ["Canadian Urological Association Journal"], "link": [{"URL": "http://www.cuaj.ca/index.php/journal/article/viewFile/4292/2945", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.cuaj.ca/index.php/journal/article/viewFile/4292/2945", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 9, 11]], "date-time": "2017-09-11T15:45:34Z", "timestamp": 1505144734000}, "score": 46.72888, "issued": {"date-parts": [[2016, 12, 15]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 12, 15]]}, "issue": "11-12"}, "URL": "http://dx.doi.org/10.5489/cuaj.4292", "ISSN": ["1920-1214", "1911-6470"], "issn-type": [{"value": "1911-6470", "type": "print"}, {"value": "1920-1214", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T12:24:52Z", "timestamp": 1574252692293}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "12", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2006, 11, 1]], "date-time": "2006-11-01T00:00:00Z", "timestamp": 1162339200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2006, 11]]}, "DOI": "10.1016/s1359-6349(06)70540-7", "type": "journal-article", "created": {"date-parts": [[2006, 12, 22]], "date-time": "2006-12-22T22:36:58Z", "timestamp": 1166827018000}, "page": "162", "source": "Crossref", "is-referenced-by-count": 0, "title": ["535 POSTER AZD2171, a highly potent, orally active VEGF signalling inhibitor, enhances the effect of fractionated radiotherapy in human lung tumour xenografts"], "prefix": "10.1016", "volume": "4", "author": [{"given": "K.", "family": "Williams", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Shannon", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Telfer", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Babur", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "Stratford", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Wedge", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634906705407?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634906705407?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 10]], "date-time": "2019-01-10T16:20:17Z", "timestamp": 1547137217000}, "score": 45.38841, "issued": {"date-parts": [[2006, 11]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2006, 11]]}, "issue": "12"}, "alternative-id": ["S1359634906705407"], "URL": "http://dx.doi.org/10.1016/s1359-6349(06)70540-7", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T06:10:48Z", "timestamp": 1574316648952}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "8", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Molecular Cancer Therapeutics"], "published-print": {"date-parts": [[2007, 8, 1]]}, "DOI": "10.1158/1535-7163.mct-07-0142", "type": "journal-article", "created": {"date-parts": [[2007, 8, 15]], "date-time": "2007-08-15T18:13:10Z", "timestamp": 1187201590000}, "page": "2198-2208", "source": "Crossref", "is-referenced-by-count": 42, "title": ["Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts"], "prefix": "10.1158", "volume": "6", "author": [{"given": "N. R.", "family": "Smith", "sequence": "first", "affiliation": []}, {"given": "N. H.", "family": "James", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "Oakley", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Wainwright", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Copley", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Kendrew", "sequence": "additional", "affiliation": []}, {"given": "L. M.", "family": "Womersley", "sequence": "additional", "affiliation": []}, {"given": "J. M.", "family": "Jurgensmeier", "sequence": "additional", "affiliation": []}, {"given": "S. R.", "family": "Wedge", "sequence": "additional", "affiliation": []}, {"given": "S. T.", "family": "Barry", "sequence": "additional", "affiliation": []}], "member": "1086", "container-title": ["Molecular Cancer Therapeutics"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1535-7163.MCT-07-0142", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 22]], "date-time": "2016-12-22T23:53:09Z", "timestamp": 1482450789000}, "score": 44.82942, "issued": {"date-parts": [[2007, 8, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2007, 8, 1]]}, "issue": "8"}, "URL": "http://dx.doi.org/10.1158/1535-7163.mct-07-0142", "ISSN": ["1535-7163", "1538-8514"], "issn-type": [{"value": "1535-7163", "type": "print"}, {"value": "1538-8514", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T21:00:19Z", "timestamp": 1574370019771}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2008, 5, 15]]}, "DOI": "10.1158/1078-0432.ccr-07-4783", "type": "journal-article", "created": {"date-parts": [[2008, 5, 15]], "date-time": "2008-05-15T18:38:35Z", "timestamp": 1210876715000}, "page": "3124-3131", "source": "Crossref", "is-referenced-by-count": 54, "title": ["Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy"], "prefix": "10.1158", "volume": "14", "author": [{"given": "J. O.", "family": "Curwen", "sequence": "first", "affiliation": []}, {"given": "H. L.", "family": "Musgrove", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Kendrew", "sequence": "additional", "affiliation": []}, {"given": "G. H.P.", "family": "Richmond", "sequence": "additional", "affiliation": []}, {"given": "D. J.", "family": "Ogilvie", "sequence": "additional", "affiliation": []}, {"given": "S. R.", "family": "Wedge", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2008, 5, 15]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-07-4783", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T10:52:12Z", "timestamp": 1482490332000}, "score": 43.569286, "issued": {"date-parts": [[2008, 5, 15]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2008, 5, 15]]}, "published-print": {"date-parts": [[2008, 5, 15]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-07-4783", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T11:31:11Z", "timestamp": 1574335871664}, "publisher-location": "Berlin, Heidelberg", "reference-count": 158, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783540331766", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/978-3-540-33177-3_23", "type": "book-chapter", "created": {"date-parts": [[2007, 12, 4]], "date-time": "2007-12-04T01:57:51Z", "timestamp": 1196733471000}, "page": "395-423", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Vascular Endothelial Growth Factor"], "prefix": "10.1007", "author": [{"given": "Stephen R.", "family": "Wedge", "sequence": "first", "affiliation": []}, {"given": "Juliane M.", "family": "J\u00fcrgensmeier", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "23_CR1", "doi-asserted-by": "crossref", "first-page": "548", "DOI": "10.1073/pnas.95.2.548", "volume": "95", "author": "M.G. Achen", "year": "1998", "unstructured": "Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95:548\u2013553", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "23_CR2", "doi-asserted-by": "crossref", "first-page": "75", "DOI": "10.1023/A:1021507031486", "volume": "5", "author": "N. Akhtar", "year": "2002", "unstructured": "Akhtar N, Dickerson EB, Auerbach R (2002) The sponge/ Matrigel angiogenesis assay. Angiogenesis 5:75\u201380", "journal-title": "Angiogenesis"}, {"key": "23_CR3", "doi-asserted-by": "crossref", "first-page": "94", "DOI": "10.1126/science.1082015", "volume": "301", "author": "A. Alavi", "year": "2003", "unstructured": "Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA (2003) Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301:94\u201396", "journal-title": "Science"}, {"key": "23_CR4", "unstructured": "Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Li J, Guo J, Ghoreishi-Haack NS, Brooks JV, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Wei RQ, McCall JO, Bouska JJ, Luo L, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK (2005) Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor. Proc Am Assoc Cancer Res abstr676"}, {"key": "23_CR5", "doi-asserted-by": "crossref", "first-page": "1375", "DOI": "10.1093/jnci/93.18.1375", "volume": "93", "author": "O. Alper", "year": "2001", "unstructured": "Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG (2001) Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93:1375\u20131384", "journal-title": "J Natl Cancer Inst"}, {"key": "23_CR6", "unstructured": "Amiri P, Aikawa ME, Dove J, Stuart DD, Poon D, Pick T, Ramurthy S, Subramanian S, Levine B, Costales A, Harris A, Paul R (2006) CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. Proc Am Assoc Cancer Res 47 abstr 4855"}, {"key": "23_CR7", "doi-asserted-by": "crossref", "first-page": "457", "DOI": "10.1002/cncr.11073", "volume": "97", "author": "M. Arinaga", "year": "2003", "unstructured": "Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y (2003) Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97:457\u2013464", "journal-title": "Cancer"}, {"key": "23_CR8", "first-page": "1231", "volume": "9", "author": "C.L. Arteaga", "year": "2003", "unstructured": "Arteaga CL (2003) Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? Clin Cancer Res 9:1231\u20131232", "journal-title": "Clin Cancer Res"}, {"key": "23_CR9", "doi-asserted-by": "crossref", "first-page": "964", "DOI": "10.1126/science.275.5302.964", "volume": "275", "author": "T. Asahara", "year": "1997", "unstructured": "Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964\u2013967", "journal-title": "Science"}, {"key": "23_CR10", "doi-asserted-by": "crossref", "first-page": "83", "DOI": "10.1016/j.ccr.2006.11.021", "volume": "11", "author": "T.T. Batchelor", "year": "2007", "unstructured": "Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83\u201395", "journal-title": "Cancer Cell"}, {"key": "23_CR11", "doi-asserted-by": "crossref", "first-page": "83", "DOI": "10.1111/j.1549-8719.1999.tb00091.x", "volume": "6", "author": "D.O. Bates", "year": "1999", "unstructured": "Bates DO, Lodwick D, Williams B (1999) Vascular endothelial growth factor and microvascular permeability. Microcirculation 6:83\u201396", "journal-title": "Microcirculation"}, {"key": "23_CR12", "first-page": "7301", "volume": "63", "author": "J.S. Beebe", "year": "2003", "unstructured": "Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG (2003) Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63:7301\u20137309", "journal-title": "Cancer Res"}, {"key": "23_CR13", "unstructured": "Bello C, Laurie S, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus K (2005) Food does not effect the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor, in healthy subjects. Clin Cancer Res 11 abstr B175"}, {"key": "23_CR14", "doi-asserted-by": "crossref", "first-page": "159", "DOI": "10.1172/JCI5028", "volume": "103", "author": "L.E. Benjamin", "year": "1999", "unstructured": "Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159\u2013165", "journal-title": "J Clin Invest"}, {"key": "23_CR15", "doi-asserted-by": "crossref", "first-page": "1287", "DOI": "10.1172/JCI200317929", "volume": "111", "author": "G. Bergers", "year": "2003", "unstructured": "Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287\u20131295", "journal-title": "J Clin Invest"}, {"key": "23_CR16", "unstructured": "Bozec A, Formento P, Fischel J-L, Hofman P, Etienne M-C, Milano G (2006) Combined effect of EGFR targeting with antiangiogenesis and irradiation. Proc Am Assoc Cancer Res 47 abstr 232"}, {"key": "23_CR17", "unstructured": "Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton JC, Kendrew J, Wedge SR (2007) The effects of AZD2171 and ZD6474 (ZACTIMA\u2122) on haemodynamic parameters in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced magnetic resonance imaging and the rapid clearance blood pool contrast agent gadomelitol. NMR Biomed (in press)", "DOI": "10.1002/nbm.1161", "doi-asserted-by": "crossref"}, {"key": "23_CR18", "first-page": "5721", "volume": "9", "author": "A.T. Byrne", "year": "2003", "unstructured": "Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721\u20135728", "journal-title": "Clin Cancer Res"}, {"key": "23_CR19", "first-page": "7284", "volume": "62", "author": "F. Carlomagno", "year": "2002", "unstructured": "Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284\u20137290", "journal-title": "Cancer Res"}, {"key": "23_CR20", "unstructured": "Chang YS, Cortes C, Polony B, Brink C, Elting JJ (2005) Preclinical chemotherapy with the VEGFR-2 and PDGFR inhibitor, BAY 57\u20139352, in combination with capecitabine and paclitaxel. Proc Am Assoc Cancer Res abstr 2030"}, {"key": "23_CR21", "doi-asserted-by": "crossref", "first-page": "1889", "DOI": "10.1038/sj.bjc.6601386", "volume": "89", "author": "D. Checkley", "year": "2003", "unstructured": "Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR (2003) Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89:1889\u20131895", "journal-title": "Br J Cancer"}, {"key": "23_CR22", "doi-asserted-by": "crossref", "first-page": "293", "DOI": "10.1007/s11912-005-0053-6", "volume": "7", "author": "L.L. Chen", "year": "2005", "unstructured": "Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS (2005) Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7:293\u2013299", "journal-title": "Curr Oncol Rep"}, {"key": "23_CR23", "doi-asserted-by": "crossref", "first-page": "172", "DOI": "10.1002/ijc.1335", "volume": "93", "author": "F. Ciardiello", "year": "2001", "unstructured": "Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J, Bianco AR, Tortora G (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93:172\u2013178", "journal-title": "Int J Cancer"}, {"key": "23_CR24", "doi-asserted-by": "crossref", "first-page": "5472", "DOI": "10.1158/1078-0432.CCR-04-2658", "volume": "11", "author": "J.W. Clark", "year": "2005", "unstructured": "Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43\u20139006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472\u20135480", "journal-title": "Clin Cancer Res"}, {"key": "23_CR25", "unstructured": "Cohen RB, Simon G, Langer CJ, Schol JR, McHale J, Eisenberg P, Hainsworth JD, Liau KF, Healey D (2004) Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 22 abstr 3014"}, {"key": "23_CR26", "unstructured": "Curwen JO, Musgrove HL, Graham GA, Kendrew J, Richmond GHP, Ogilvie DJ, Wedge SR (2005) Management of hypertension induced by AZD2171, an oral, highly potent and reversible VEGFR signaling inhibitor, in rat. Clin Cancer Res 11 abstr B9"}, {"key": "23_CR27", "doi-asserted-by": "crossref", "first-page": "949", "DOI": "10.1038/nature00766", "volume": "417", "author": "H. Davies", "year": "2002", "unstructured": "Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigier HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954", "journal-title": "Nature"}, {"key": "23_CR28", "unstructured": "Demetri G, van Oosterom AT, Garrett C, Blackstein M, Shah M, Verweij JJ, McArthur G, Judson I, Baum C, Casali P (2006) Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a Phase III trial. Proc Am Soc Clin Oncol abstr 8"}, {"key": "23_CR29", "doi-asserted-by": "crossref", "first-page": "1619", "DOI": "10.1038/sj.onc.1202478", "volume": "18", "author": "M. Dougher", "year": "1999", "unstructured": "Dougher M, Terman BI (1999) Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18:1619\u20131627", "journal-title": "Oncogene"}, {"key": "23_CR30", "first-page": "4015", "volume": "62", "author": "J. Drevs", "year": "2002", "unstructured": "Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marme D (2002) PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62:4015\u20134022", "journal-title": "Cancer Res"}, {"key": "23_CR31", "first-page": "1051", "volume": "45", "author": "J. Drevs", "year": "2004", "unstructured": "Drevs J, Esser N, Wedge SR, Ryan AJ, Oglivie DJ, Marme D (2004) Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma. Proc Am Assoc Cancer Res 45:1051", "journal-title": "Proc Am Assoc Cancer Res"}, {"key": "23_CR32", "doi-asserted-by": "crossref", "first-page": "558", "DOI": "10.1093/annonc/mdi118", "volume": "16", "author": "J. Drevs", "year": "2005", "unstructured": "Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marme D (2005) Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16:558\u2013565", "journal-title": "Ann Oncol"}, {"key": "23_CR33", "unstructured": "Drevs J, Siegert P, Medinger M, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, J\u00fcrgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C (2007) Phase I clinical study of AZD2171, an oral, highly potent VEGF signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol (in press)", "DOI": "10.1200/JCO.2006.07.2066", "doi-asserted-by": "crossref"}, {"key": "23_CR34", "doi-asserted-by": "crossref", "first-page": "233", "DOI": "10.1159/000236988", "volume": "107", "author": "H.F. Dvorak", "year": "1995", "unstructured": "Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de WL, Senger DR (1995) Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107:233\u2013235", "journal-title": "Int Arch Allergy Immunol"}, {"issue": "[Suppl 2]", "key": "23_CR35", "doi-asserted-by": "crossref", "first-page": "S55", "DOI": "10.3816/CCC.2004.s.009", "volume": "4", "author": "L.M. Ellis", "year": "2004", "unstructured": "Ellis LM (2004) Preclinical data targeting vascular endothelial growth factor in colorectal cancer. Clin Colorectal Cancer 4[Suppl 2]:S55\u2013S61", "journal-title": "Clin Colorectal Cancer"}, {"key": "23_CR36", "unstructured": "Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43\u20139006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol abstr 4510", "DOI": "10.1200/jco.2005.23.16_suppl.lba4510", "doi-asserted-by": "crossref"}, {"key": "23_CR37", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1200/JCO.2005.02.2194", "volume": "24", "author": "S. Faivre", "year": "2006", "unstructured": "Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25\u201335", "journal-title": "J Clin Oncol"}, {"key": "23_CR38", "doi-asserted-by": "crossref", "first-page": "2647", "DOI": "10.1038/sj.onc.1208246", "volume": "24", "author": "F. Fan", "year": "2005", "unstructured": "Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24:2647\u20132653", "journal-title": "Oncogene"}, {"key": "23_CR39", "unstructured": "Fargnoli J, Bhide R, Lombardo L, Hunt JT, Cai ZW, Barrish J, Galbraith S, Jeyaseelan R, Mortillo S, Kukral D, Wautlet B, Krishnan B, Lewin A, Henley B (2005) Preclinical studies of BMS-582664, an alanine prodrug of BMS-540215, a potent, dual inhibitor of VEGFR-2 and FGFR-1 kinases. Proc Am Assoc Cancer Res abstr 3033"}, {"key": "23_CR40", "doi-asserted-by": "crossref", "first-page": "795", "DOI": "10.1038/nrc909", "volume": "2", "author": "N. Ferrara", "year": "2002", "unstructured": "Ferrara N (2002a) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795\u2013803", "journal-title": "Nat Rev Cancer"}, {"key": "23_CR41", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1053/sonc.2002.37264", "volume": "29", "author": "N. Ferrara", "year": "2002", "unstructured": "Ferrara N (2002b) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10\u201314", "journal-title": "Semin Oncol"}, {"key": "23_CR42", "doi-asserted-by": "crossref", "first-page": "336", "DOI": "10.1038/nm0398-336", "volume": "4", "author": "N. Ferrara", "year": "1998", "unstructured": "Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336\u2013340", "journal-title": "Nat Med"}, {"key": "23_CR43", "unstructured": "Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega NM, Gentile A, Ljubimir V, Pithavala YK, Bokemeyer C, Boven E (2005) Phase I study of SU014813, a novel oral multitargeted receptor tyrosine kinase (RTK) inhibitor. Proc AACR-NCI-EORTC abstr B119"}, {"key": "23_CR44", "first-page": "679", "volume": "151", "author": "D. Fukumura", "year": "1997", "unstructured": "Fukumura D, Yuan F, Monsky WL, Chen Y, Jain RK (1997) Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 151:679\u2013688", "journal-title": "Am J Pathol"}, {"key": "23_CR45", "doi-asserted-by": "crossref", "first-page": "1446", "DOI": "10.1158/0008-5472.CAN-05-1661", "volume": "66", "author": "C.A. Garces", "year": "2006", "unstructured": "Garces CA, Kurenova EV, Golubovskaya VM, Cance WG (2006) Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 66:1446\u20131454", "journal-title": "Cancer Res"}, {"key": "23_CR46", "doi-asserted-by": "crossref", "first-page": "1015", "DOI": "10.1158/0008-5472.CAN-05-2873", "volume": "66", "author": "A.J. Garton", "year": "2006", "unstructured": "Garton AJ, Crew AP, Franklin M, Cooke AR, Wynne GM, Castaldo L, Kahler J, Winski SL, Franks A, Brown EN, Bittner MA, Keily JF, Briner P, Hidden C, Srebernak MC, Pirrit C, O\u2019Connor M, Chan A, Vulevic B, Henninger D, Hart K, Sennello R, Li AH, Zhang T, Richardson F, Emerson DL, Castelhano AL, Arnold LD, Gibson NW (2006) OSI-930: a novel selective inhibitor of Kit andkinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res 66:1015\u20131024", "journal-title": "Cancer Res"}, {"key": "23_CR47", "first-page": "3106", "volume": "95", "author": "U.M. Gehling", "year": "2000", "unstructured": "Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N, Kluge K, Schafer B, Hossfeld DK, Fiedler W (2000) In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:3106\u20133112", "journal-title": "Blood"}, {"key": "23_CR48", "doi-asserted-by": "crossref", "first-page": "623", "DOI": "10.1038/9467", "volume": "5", "author": "H.P. Gerber", "year": "1999", "unstructured": "Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623\u2013628", "journal-title": "Nat Med"}, {"key": "23_CR49", "doi-asserted-by": "crossref", "first-page": "3222", "DOI": "10.1074/jbc.M002016200", "volume": "276", "author": "H. Gille", "year": "2001", "unstructured": "Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptorspecific vascular endothelial growth factor mutants. J Biol Chem 276:3222\u20133230", "journal-title": "J Biol Chem"}, {"key": "23_CR50", "unstructured": "Goldbeck C, Shephard LB, Louie SG, Lee SH, Lea A, Heise. C.C. (2005) Development of pharmacodynamic endpoint assays for use in clinical trials of CHIR-258, a multitargeted receptor tyrosine kinase inhibitor. Proc Am Assoc Cancer Res abstr 465"}, {"issue": "12", "key": "23_CR51", "first-page": "108", "volume": "4", "author": "B.C. Goh", "year": "2006", "unstructured": "Goh BC, Thng CH, Sukri N, Wong CI, Soo R, Carr R, Lee SC, Chen CS, Humerickhouse R (2006) Phase I study of ABT869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. Eur J Cancer [Suppl] 4(12) abstr 108", "journal-title": "Eur J Cancer"}, {"key": "23_CR52", "doi-asserted-by": "crossref", "first-page": "2133", "DOI": "10.1093/carcin/bgl113", "volume": "10", "author": "R.A. Goodlad", "year": "2006", "unstructured": "Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, Smith NR, Mandir N, Watkins AJ, Wilkinson RW (2006) Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 10: 2133\u20132139", "journal-title": "Carcinogenesis"}, {"key": "23_CR53", "first-page": "1445", "volume": "127", "author": "J.J. Haigh", "year": "2000", "unstructured": "Haigh JJ, Gerber HP, Ferrara N, Wagner EF (2000) Conditional inactivation of VEGF-A in areas of collagen2al expression results in embryonic lethality in the heterozygous state. Development 127:1445\u20131453", "journal-title": "Development"}, {"key": "23_CR54", "doi-asserted-by": "crossref", "first-page": "131", "DOI": "10.1080/01926230600611836", "volume": "34", "author": "A.P. Hall", "year": "2006", "unstructured": "Hall AP, Westwood FR, Wadsworth PF (2006) Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 34:131\u2013147", "journal-title": "Toxicol Pathol"}, {"key": "23_CR55", "doi-asserted-by": "crossref", "first-page": "689", "DOI": "10.1677/erc.1.00600", "volume": "11", "author": "P.M. Harari", "year": "2004", "unstructured": "Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689\u2013708", "journal-title": "Endocr Relat Cancer"}, {"key": "23_CR56", "unstructured": "Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K, Bodoky G, Borner M, Laurent D, Jacques C (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol abstr 3", "DOI": "10.1200/jco.2005.23.16_suppl.lba3", "doi-asserted-by": "crossref"}, {"key": "23_CR57", "unstructured": "Herbst R, Kurzrock R, Parson M, Benjamin R, Chen L, Ng C, Ingram M, Wong S, Chang D, Rosen L (2004) AMG 706 first in human, open-label, dose-finding study evaluating the safety and pharmacokinetics (PK) in subjects with advanced solid tumors. EJC Suppl 2:48", "DOI": "10.1016/S1359-6349(04)80159-9", "doi-asserted-by": "crossref"}, {"key": "23_CR58", "unstructured": "Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Herbst RS (2005) A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Proc Am Soc Clin Oncol abstr 3023", "DOI": "10.1200/jco.2005.23.16_suppl.3023", "doi-asserted-by": "crossref"}, {"key": "23_CR59", "doi-asserted-by": "crossref", "first-page": "50", "DOI": "10.1016/S1359-6349(04)80166-6", "volume": "2", "author": "F Hilberg", "year": "2004", "unstructured": "Hilberg F, Tontsch-Grunt U, Colbatzky F, Heckel A, Lotz R, van Meel JCA, Roth GJ (2004) BIBF1120 a novel, small molecule triple angiokinase inhibitor: profiling as a clinical candidate for cancer therapy. EJC Suppl 2:50", "journal-title": "EJC Suppl"}, {"key": "23_CR60", "doi-asserted-by": "crossref", "first-page": "176", "DOI": "10.1159/000051044", "volume": "38", "author": "N.J. Hillman", "year": "2001", "unstructured": "Hillman NJ, Whittles CE, Pocock TM, Williams B, Bates DO (2001) Differential effects of vascular endothelial growth factor-C and placental growth factor-1 on the hydraulic conductivity of frog mesenteric capillaries. J Vasc Res 38:176\u2013186", "journal-title": "J Vasc Res"}, {"key": "23_CR61", "doi-asserted-by": "crossref", "first-page": "11393", "DOI": "10.1073/pnas.172398299", "volume": "99", "author": "J. Holash", "year": "2002", "unstructured": "Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393\u201311398", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "23_CR62", "doi-asserted-by": "crossref", "first-page": "22267", "DOI": "10.1074/jbc.M312729200", "volume": "279", "author": "K. Holmqvist", "year": "2004", "unstructured": "Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T, Claesson-Welsh L, Welsh M (2004) The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279:22267\u201322275", "journal-title": "J Biol Chem"}, {"key": "23_CR63", "doi-asserted-by": "crossref", "first-page": "519", "DOI": "10.1046/j.1469-7580.1999.19440519.x", "volume": "194", "author": "A. Horner", "year": "1999", "unstructured": "Horner A, Bishop NJ, Bord S, Beeton C, Kelsall AW, Coleman N, Compston JE (1999) Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage. J Anat 194:519\u2013524", "journal-title": "J Anat"}, {"key": "23_CR64", "doi-asserted-by": "crossref", "first-page": "173", "DOI": "10.1006/jsre.2001.6089", "volume": "96", "author": "T.R. Howdieshell", "year": "2001", "unstructured": "Howdieshell TR, Callaway D, Webb WL, Gaines MD, Procter CD Jr, Sathyanarayana, Pollock JS, Brock TL, McNeil PL (2001) Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 96:173\u2013182", "journal-title": "J Surg Res"}, {"key": "23_CR65", "first-page": "418", "volume": "3", "author": "S. Hunt", "year": "2001", "unstructured": "Hunt S (2001) Technology evaluation: IMC-1C11, ImClone Systems. Curr Opin Mol Ther 3:418\u2013424", "journal-title": "Curr Opin Mol Ther"}, {"key": "23_CR66", "doi-asserted-by": "crossref", "first-page": "2335", "DOI": "10.1056/NEJMoa032691", "volume": "350", "author": "H. Hurwitz", "year": "2004", "unstructured": "Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342", "journal-title": "N Engl J Med"}, {"key": "23_CR67", "unstructured": "Hurwitz H, Dowlati A, Savage S, Fernando N, Lasalvia S, Whitehead B, Suttle B, Collins D, Ho P, Pandite L (2005) Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. Proc Am Soc Clin Oncol abstr 3012", "DOI": "10.1200/jco.2005.23.16_suppl.3012", "doi-asserted-by": "crossref"}, {"key": "23_CR68", "doi-asserted-by": "crossref", "first-page": "197", "DOI": "10.1016/S0304-3835(03)00456-7", "volume": "204", "author": "M. Ichihara", "year": "2004", "unstructured": "Ichihara M, Murakumo Y, Takahashi M (2004) RET and neuroendocrine tumors. Cancer Lett 204:197\u2013211", "journal-title": "Cancer Lett"}, {"key": "23_CR69", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1016/S0002-9440(10)63273-7", "volume": "165", "author": "T. Inai", "year": "2004", "unstructured": "Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35\u201352", "journal-title": "Am J Pathol"}, {"key": "23_CR70", "doi-asserted-by": "crossref", "first-page": "685", "DOI": "10.1038/nm0603-685", "volume": "9", "author": "R.K. Jain", "year": "2003", "unstructured": "Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685\u2013693", "journal-title": "Nat Med"}, {"key": "23_CR71", "doi-asserted-by": "crossref", "first-page": "34", "DOI": "10.1002/path.1943", "volume": "209", "author": "B. Jenny", "year": "2006", "unstructured": "Jenny B, Harrison J, Baetens D, Tille JC, Burkhardt K, Mottaz H, Kiss J, Dietrich PY, De Tribolet N, Pizzolato G, Pepper M (2006) Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 209:34\u201343", "journal-title": "J Pathol"}, {"key": "23_CR72", "doi-asserted-by": "crossref", "first-page": "1751", "DOI": "10.1002/j.1460-2075.1996.tb00521.x", "volume": "15", "author": "V. Joukov", "year": "1996", "unstructured": "Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996a) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:1751", "journal-title": "EMBO J"}, {"key": "23_CR73", "doi-asserted-by": "crossref", "first-page": "290", "DOI": "10.1002/j.1460-2075.1996.tb00359.x", "volume": "15", "author": "V. Joukov", "year": "1996", "unstructured": "Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K (1996b) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290\u2013298", "journal-title": "EMBO J"}, {"key": "23_CR74", "unstructured": "J\u00fcrgensmeier JM, Brave SR, James NH, Wedge SR, Oglivie DJ, Barry ST (2005) AZD2171, a highly potent inhibitor of VEGF receptor signaling, has additional activity versus the c-Kit receptor tyrosine kinase. Proc Am Assoc Cancer Res 46 abstr 5834"}, {"key": "23_CR75", "doi-asserted-by": "crossref", "first-page": "74", "DOI": "10.1038/ni1013", "volume": "5", "author": "M.J. Karkkainen", "year": "2004", "unstructured": "Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 5:74\u201380", "journal-title": "Nat Immunol"}, {"key": "23_CR76", "doi-asserted-by": "crossref", "first-page": "6453", "DOI": "10.1074/jbc.274.10.6453", "volume": "274", "author": "R.L. Kendall", "year": "1999", "unstructured": "Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA (1999) Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J Biol Chem 274:6453\u20136460", "journal-title": "J Biol Chem"}, {"key": "23_CR77", "doi-asserted-by": "crossref", "first-page": "213", "DOI": "10.1593/neo.03394", "volume": "6", "author": "F. Kiessling", "year": "2004", "unstructured": "Kiessling F, Farhan N, Lichy MP, Vosseier S, Heilmann M, Krix M, Bohlen P, Miller DW, Mueller MM, Semmler W, Fusenig NE, Delorme S (2004) Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 6:213\u2013223", "journal-title": "Neoplasia"}, {"key": "23_CR78", "doi-asserted-by": "crossref", "first-page": "11399", "DOI": "10.1073/pnas.172398399", "volume": "99", "author": "E.S. Kim", "year": "2002", "unstructured": "Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ (2002) Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99:11399\u201311404", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "23_CR79", "first-page": "1454", "volume": "63", "author": "E.T. Kimura", "year": "2003", "unstructured": "Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454\u20131457", "journal-title": "Cancer Res"}, {"key": "23_CR80", "first-page": "1048", "volume": "45", "author": "T.C. Klinowska", "year": "2004", "unstructured": "Klinowska TC, Jackson JA, Farrington PM, Smith DS, Barnett S, Whittaker L, Bigley AL, Wadsworth PF, Oglivie DJ, Wedge SR (2004) AZD2171, a highly potent inhibitor of VEGF receptor tyrosine kinase activity, inhibits the growth of spontaneous mammary tumors in the MMTV-neu transgenic mouse. Proc Am Assoc Cancer Res 45:1048", "journal-title": "Proc Am Assoc Cancer Res"}, {"key": "23_CR81", "unstructured": "Kumar R, Harrington LE, Hopper TM, Miller CG, Onori JA, Cheung M, Stafford JA, Epperly AH, Gilmer TM (2005) Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. Proc Am Soc Clin Oncol abstr 9537", "DOI": "10.1200/jco.2005.23.16_suppl.9537", "doi-asserted-by": "crossref"}, {"key": "23_CR82", "doi-asserted-by": "crossref", "first-page": "S23", "DOI": "10.1053/j.seminoncol.2005.10.005", "volume": "32", "author": "C.J. Langer", "year": "2005", "unstructured": "Langer CJ, Natale RB (2005) The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol 32:S23\u2013S29", "journal-title": "Semin Oncol"}, {"key": "23_CR83", "doi-asserted-by": "crossref", "first-page": "3995", "DOI": "10.1128/MCB.21.12.3995-4004.2001", "volume": "21", "author": "E. Laughner", "year": "2001", "unstructured": "Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxiainducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995\u20134004", "journal-title": "Mol Cell Biol"}, {"key": "23_CR84", "doi-asserted-by": "crossref", "first-page": "3633", "DOI": "10.1158/1078-0432.CCR-04-2129", "volume": "11", "author": "S.H. Lee", "year": "2005", "unstructured": "Lee SH, Lopes DM, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11:3633\u20133641", "journal-title": "Clin Cancer Res"}, {"key": "23_CR85", "doi-asserted-by": "crossref", "first-page": "96", "DOI": "10.1053/sonc.2002.34061", "volume": "29", "author": "W. Liu", "year": "2002", "unstructured": "Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Fan F, Ahmad SA, Jung YD, Ellis LM (2002) Antiangiogenic therapy targeting factors that enhance endothelial cell survival. Semin Oncol 29:96\u2013103", "journal-title": "Semin Oncol"}, {"key": "23_CR86", "doi-asserted-by": "crossref", "first-page": "5464", "DOI": "10.1200/JCO.2005.04.143", "volume": "23", "author": "G. Liu", "year": "2005", "unstructured": "Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a Phase I study. J Clin Oncol 23:5464\u20135473", "journal-title": "J Clin Oncol"}, {"key": "23_CR87", "unstructured": "Mamluk R, Storek MJ, Gokemeijer J, Bates JM, Morse BM, Robinson JJ, Gosselin ML, Harris AS (2006) CT-322: a novel protein therapeutic with favorable pharmacokinetics and biodistribution. Proc Am Assoc Cancer Res 47 abstr 230"}, {"key": "23_CR88", "doi-asserted-by": "crossref", "first-page": "1912", "DOI": "10.1126/science.1075762", "volume": "298", "author": "G. Manning", "year": "2002", "unstructured": "Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912\u20131934", "journal-title": "Science"}, {"key": "23_CR89", "unstructured": "Martinelli E, Takimoto CH, van Oosterom AT, Tabernero J, Rowinsky E, Schoffski P, Huang J, Casado E, Mita A, Dumez H (2005) AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: preliminary phase 1 results. Proc Am Soc Clin Oncol abstr 3039", "DOI": "10.1200/jco.2005.23.16_suppl.3039", "doi-asserted-by": "crossref"}, {"key": "23_CR90", "unstructured": "Matsui J, Obaishi H, Watanabe T, Yamaguchi A, Suzuki S, Yamamoto Y, Nakamura K, Nomoto K, Mimura F, Funahashi Y, Matsushima T, Miyazaki K, Haneda T, Fukuda Y, Kamata J, Takahashi K, Matsukura M, Tsuruoka, Asada M, Yoshimatsu K (2003) E7080(ER-203492-00), a novel VEGF receptor tyrosine kinase inhibitor-I. Characterisation a an angiogenesis inhibitor. Proc Am Assoc Cancer Res abstr 51"}, {"key": "23_CR91", "doi-asserted-by": "crossref", "first-page": "2342", "DOI": "10.1038/sj.emboj.7600709", "volume": "24", "author": "T. Matsumoto", "year": "2005", "unstructured": "Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, Wu J, Bruheim S, Mugishima H, Mukhopadhyay D, Spurkland A, Claesson-Welsh L (2005) VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24:2342\u20132353", "journal-title": "EMBO J"}, {"key": "23_CR92", "doi-asserted-by": "crossref", "first-page": "472", "DOI": "10.1016/S8756-3282(01)00690-1", "volume": "30", "author": "U. Mayr-Wohlfart", "year": "2002", "unstructured": "Mayr-Wohlfart U, Waltenberger J, Hausser H, Kessler S, G\u00fcnther KP, Dehio C, Puhl W, Brenner RE (2002) Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 30:472\u2013477", "journal-title": "Bone"}, {"key": "23_CR93", "doi-asserted-by": "crossref", "first-page": "319", "DOI": "10.1016/S0969-2126(99)80042-2", "volume": "7", "author": "M.A. McTigue", "year": "1999", "unstructured": "McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, Tempczyk-Russell A, Gehring MR, Mroczkowski B, Kan CC, Villafranca JE, Appelt K (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 7:319\u2013330", "journal-title": "Structure"}, {"key": "23_CR94", "first-page": "327", "volume": "9", "author": "D.B. Mendel", "year": "2003", "unstructured": "Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337", "journal-title": "Clin Cancer Res"}, {"key": "23_CR95", "doi-asserted-by": "crossref", "first-page": "363", "DOI": "10.1093/emboj/18.2.363", "volume": "18", "author": "M. Meyer", "year": "1999", "unstructured": "Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha HJ, Dehio C (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18:363\u2013374", "journal-title": "EMBO J"}, {"key": "23_CR96", "unstructured": "Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkler TN, Davidson NE (2005) A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. ASCO Oral presentation: no abstract available"}, {"key": "23_CR97", "doi-asserted-by": "crossref", "first-page": "281", "DOI": "10.1158/1078-0432.CCR-05-0219", "volume": "12", "author": "K.D. Miller", "year": "2006", "unstructured": "Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW Jr (2006) A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin Cancer Res 12:281\u2013288", "journal-title": "Clin Cancer Res"}, {"key": "23_CR98", "unstructured": "Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N (2003) A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 194"}, {"key": "23_CR99", "doi-asserted-by": "crossref", "first-page": "3955", "DOI": "10.1200/JCO.2003.08.092", "volume": "21", "author": "B. Morgan", "year": "2003", "unstructured": "Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield KM, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O\u2019Byrne KJ, Henry A, Cherryman GR, Leurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrokine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J Clin Oncol 21:3955\u20133964", "journal-title": "J Clin Oncol"}, {"key": "23_CR100", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1200/JCO.2005.02.2574", "volume": "24", "author": "R.J. Motzer", "year": "2006", "unstructured": "Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324", "journal-title": "J Clin Oncol"}, {"key": "23_CR101", "doi-asserted-by": "crossref", "first-page": "44", "DOI": "10.1016/S1359-6349(04)80144-7", "volume": "2", "author": "K Mross", "year": "2004", "unstructured": "Mross K, Baas F, Medinger M, Drevs J, Strecker R, Hennig J, Wolters M, Stehle G, Stefanic M (2004) A clinical phase I dose escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of BIBF 1120 in advanced cancer patients. EJC Suppl 2:44", "journal-title": "EJC Suppl"}, {"key": "23_CR102", "unstructured": "Mross KB, Gmehling D, Frost A, Baas F, Strecker R, Hennig J, Stopfer P, Stefanie M, Stehle G, de Rossi L (2005) A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients. Proc Am Soc Clin Oncol abstr 3031", "DOI": "10.1200/jco.2005.23.16_suppl.3031", "doi-asserted-by": "crossref"}, {"key": "23_CR103", "doi-asserted-by": "crossref", "first-page": "105", "DOI": "10.1016/0092-8674(88)90184-5", "volume": "54", "author": "W.J. M\u00fcller", "year": "1988", "unstructured": "M\u00fcller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105\u2013115", "journal-title": "Cell"}, {"key": "23_CR104", "doi-asserted-by": "crossref", "first-page": "G1360", "DOI": "10.1152/ajpgi.2001.280.6.G1360", "volume": "280", "author": "L. Musallam", "year": "2001", "unstructured": "Musallam L, Ethier C, Haddad PS, Bilodeau M (2001) Role of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes. Am J Physiol Gastrointest Liver Physiol 280:G1360\u2013G1369", "journal-title": "Am J Physiol Gastrointest Liver Physiol"}, {"key": "23_CR105", "doi-asserted-by": "crossref", "first-page": "161", "DOI": "10.1016/S0014-5793(00)01520-9", "volume": "473", "author": "M. Nakagawa", "year": "2000", "unstructured": "Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y (2000) Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161\u2013164", "journal-title": "FEBS Lett"}, {"key": "23_CR106", "doi-asserted-by": "crossref", "first-page": "9134", "DOI": "10.1158/0008-5472.CAN-05-4290", "volume": "66", "author": "K. Nakamura", "year": "2006", "unstructured": "Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isoe T (2006) KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumour activities and affects functional vascular properties. Cancer Res 66: 9134\u20139142", "journal-title": "Cancer Res"}, {"issue": "[Suppl 2]", "key": "23_CR107", "doi-asserted-by": "crossref", "first-page": "S37", "DOI": "10.1016/S0169-5002(05)80237-5", "volume": "49", "author": "R. Natale", "year": "2005", "unstructured": "Natale R, Bodkin D, Govindan R, Sleckman B, Rizvi N, Capo A, Germonpre P, Dimmery I, Webster A, Ranson M (2005) A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC: results of a randomized, double-blind Phase II study. Lung Cancer 49[Suppl 2]:S37", "journal-title": "Lung Cancer"}, {"key": "23_CR108", "doi-asserted-by": "crossref", "first-page": "3597", "DOI": "10.1182/blood-2002-07-2307", "volume": "101", "author": "A.M. O\u2019Farrell", "year": "2003", "unstructured": "O\u2019Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597\u20133605", "journal-title": "Blood"}, {"key": "23_CR109", "doi-asserted-by": "crossref", "first-page": "32", "DOI": "10.1111/j.1349-7006.2004.tb03167.x", "volume": "95", "author": "S. Onogawa", "year": "2004", "unstructured": "Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K (2004) Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 95:32\u201339", "journal-title": "Cancer Sci"}, {"key": "23_CR110", "doi-asserted-by": "crossref", "first-page": "16788", "DOI": "10.1021/bi981291f", "volume": "37", "author": "C.V. Parast", "year": "1998", "unstructured": "Parast CV, Mroczkowski B, Pinko C, Misialek S, Khambatta G, Appelt K (1998) Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry 37:16788\u201316801", "journal-title": "Biochemistry"}, {"key": "23_CR111", "doi-asserted-by": "crossref", "first-page": "1774", "DOI": "10.1158/1535-7163.MCT-05-0333", "volume": "5", "author": "S. Patyna", "year": "2006", "unstructured": "Patyna S, Laird AD, Mendel DB, O\u2019Farrell A-M, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar J\u00d6, Sukbuntherng J, Zhong W-Z, Cherrington JM, Hu-Lowe D (2006) SU14813: a novel multiple tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5:1774\u20131782", "journal-title": "Mol Cancer Ther"}, {"key": "23_CR112", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1006/excr.1999.4707", "volume": "253", "author": "T.V. Petrova", "year": "1999", "unstructured": "Petrova TV, Makinen T, Alitalo K (1999) Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253:117\u2013130", "journal-title": "Exp Cell Res"}, {"key": "23_CR113", "unstructured": "Pili P, Carducci M, Robertson P, Brown P, R\u00fcssel L, Hurwitz H (2003) A phase I study of the pan-VEGFR tyrosine kinase inhibitor, CEP-7055, in patients with advanced malignancy. Proc Am Soc Clin Oncol abstr 831"}, {"key": "23_CR114", "doi-asserted-by": "crossref", "first-page": "520", "DOI": "10.1002/ijc.2910590415", "volume": "59", "author": "K.H. Plate", "year": "1994", "unstructured": "Plate KH, Breier G, Weich HA, Mennel HD, Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520\u2013529", "journal-title": "Int J Cancer"}, {"key": "23_CR115", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1046/j.1439-0264.2000.00265.x", "volume": "29", "author": "J. Plendl", "year": "2000", "unstructured": "Plendl J (2000) Angiogenesis and vascular regression in the ovary. Anat Histol Embryol 29:257\u2013266", "journal-title": "Anat Histol Embryol"}, {"key": "23_CR116", "doi-asserted-by": "crossref", "first-page": "8715", "DOI": "10.1158/0008-5472.CAN-05-4665", "volume": "66", "author": "A. Polverino", "year": "2006", "unstructured": "Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R (2006) AMG 706, an oral multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumour xenografts. Cancer Res 66:8715\u20138721", "journal-title": "Cancer Res"}, {"key": "23_CR117", "doi-asserted-by": "crossref", "first-page": "16986", "DOI": "10.1074/jbc.M000528200", "volume": "275", "author": "N. Rahimi", "year": "2000", "unstructured": "Rahimi N, Dayanir V, Lashkari K (2000) Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 275:16986\u201316992", "journal-title": "J Biol Chem"}, {"key": "23_CR118", "doi-asserted-by": "crossref", "first-page": "934", "DOI": "10.1038/418934a", "volume": "418", "author": "H. Rajagopalan", "year": "2002", "unstructured": "Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934", "journal-title": "Nature"}, {"key": "23_CR119", "unstructured": "Reardon D, Cloughesy T, Conrad C, Prados M, Xia J, Mietlowski W, Dugan M, Mischel P, Friedman H, Yung A (2005) A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Proc Am Soc Clin Oncol abstr 3063", "DOI": "10.1200/jco.2005.23.16_suppl.3063", "doi-asserted-by": "crossref"}, {"key": "23_CR120", "doi-asserted-by": "crossref", "first-page": "1028", "DOI": "10.1200/JCO.2005.01.186", "volume": "23", "author": "B.I. Rini", "year": "2005", "unstructured": "Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028\u20131043", "journal-title": "J Clin Oncol"}, {"key": "23_CR121", "doi-asserted-by": "crossref", "first-page": "2650", "DOI": "10.1158/0008-5472.CAN-05-1843", "volume": "66", "author": "N. Roberts", "year": "2006", "unstructured": "Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M (2006) Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66:2650\u20132657", "journal-title": "Cancer Res"}, {"key": "23_CR122", "doi-asserted-by": "crossref", "first-page": "3013", "DOI": "10.1200/jco.2005.23.16_suppl.3013", "volume": "23", "author": "L. Rosen", "year": "2005", "unstructured": "Rosen L, Kurzrock R, Jackson E, Wathen L, Parson M, Eschenberg M, Mulay M, Purdom M, Yan L, Herbst RS (2005) Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol (meeting abstracts) 23:3013", "journal-title": "J Clin Oncol (meeting abstracts)"}, {"key": "23_CR123", "first-page": "5978", "volume": "63", "author": "B. Ruggeri", "year": "2003", "unstructured": "Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C (2003) CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63:5978\u20135991", "journal-title": "Cancer Res"}, {"key": "23_CR124", "doi-asserted-by": "crossref", "first-page": "5474", "DOI": "10.1200/JCO.2005.04.192", "volume": "23", "author": "H.S. Rugo", "year": "2005", "unstructured": "Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474\u20135483", "journal-title": "J Clin Oncol"}, {"key": "23_CR125", "doi-asserted-by": "crossref", "first-page": "78", "DOI": "10.1177/019262339902700115", "volume": "27", "author": "A.M. Ryan", "year": "1999", "unstructured": "Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, Shopp GM, O\u2019Neill CA (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78\u201386", "journal-title": "Toxicol Pathol"}, {"key": "23_CR126", "doi-asserted-by": "crossref", "first-page": "1076", "DOI": "10.1073/pnas.0404984102", "volume": "102", "author": "Y. Sakurai", "year": "2005", "unstructured": "Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M (2005) Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA 102:1076\u20131081", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "23_CR127", "unstructured": "Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry MC, Johnson DH (2005) Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. Proc Am Soc Clin Oncol abstr LBA4", "DOI": "10.1200/jco.2005.23.16_suppl.lba4", "doi-asserted-by": "crossref"}, {"key": "23_CR128", "unstructured": "Sarker D, Evans TRJ, Hardie M, Molife R, Marriott C, Morrison R, Fox JA, Heise C, Xu X, Louie S, Aziz N, Garzon F, Skouteris G, Michelson G, Judson I, Jadayel D, Scott K, Liu W, DeBono JS (2006) CHIR-258: preliminary data from a first in human phase 1 dose escalating trial of an oral, selectively targeted receptor tyrosine kinase inhibitor in patients with solid tumours. Proc Am Soc Clin Oncol abstr 3043"}, {"key": "23_CR129", "doi-asserted-by": "crossref", "first-page": "62", "DOI": "10.1038/376062a0", "volume": "376", "author": "F. Shalaby", "year": "1995", "unstructured": "Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62\u201366", "journal-title": "Nature"}, {"key": "23_CR130", "doi-asserted-by": "crossref", "first-page": "38", "DOI": "10.1007/s10147-005-0528-3", "volume": "11", "author": "A. Shida", "year": "2006", "unstructured": "Shida A, Fujioka S, Kobayashi K, Ishibashi Y, Nimura H, Mitsumori N, Yanaga K (2006) Expression of vascular endothelial growth factor (VEGF)-C and-D in gastric carcinoma. Int J Clin Oncol 11:38\u201343", "journal-title": "Int J Clin Oncol"}, {"key": "23_CR131", "doi-asserted-by": "crossref", "first-page": "328", "DOI": "10.1111/j.1349-7006.2004.tb03211.x", "volume": "95", "author": "K. Shimizu", "year": "2004", "unstructured": "Shimizu K, Kubo H, Yamaguchi K, Kawashima K, Ueda Y, Matsuo K, Awane M, Shimahara Y, Takabayashi A, Yamaoka Y, Satoh S (2004) Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 95:328\u2013333", "journal-title": "Cancer Sci"}, {"key": "23_CR132", "doi-asserted-by": "crossref", "first-page": "768", "DOI": "10.1073/pnas.92.3.768", "volume": "92", "author": "D. Shweiki", "year": "1995", "unstructured": "Shweiki D, Neeman M, Itin A, Keshet E (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92:768\u2013772", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "23_CR133", "unstructured": "Siemeister G, Briem H, Brumby T, Jautelat R, Krueger M, Luecking U, Reichel A, Schaefer M, Mumberg D, Bosslet K (2005) ZK-304709, the oral Multitarget Tumor Growth InhibitorTM, acts via inhibition of cell cycle progression and tumor-induced angiogenesis. Proc Am Assoc Cancer Res abstr 5842"}, {"key": "23_CR134", "doi-asserted-by": "crossref", "first-page": "965", "DOI": "10.1200/JCO.2005.06.124", "volume": "23", "author": "D. Strumberg", "year": "2005", "unstructured": "Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43\u20139006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965\u2013972", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "23_CR135", "first-page": "41", "volume": "4", "author": "D. Strumberg", "year": "2006", "unstructured": "Strumberg D, Christensen O, Strecker R, Scheulen ME, Frost A, Rajagopalan P, Voliotis D, Zuehlsdorf M, Wensing G, Mross K (2006) Clinical and biomarker responses in a phase I study of BAY 57 9352 \u2014 a VEGFR-2 inhibitor \u2014 administered as continuous dosing in patients with advanced solid tumours. Eur J Cancer [Suppl] 4(12) abstr 41", "journal-title": "Eur J Cancer"}, {"key": "23_CR136", "first-page": "971", "volume": "11", "author": "M. Suggitt", "year": "2005", "unstructured": "Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11:971\u2013981", "journal-title": "Clin Cancer Res"}, {"key": "23_CR137", "unstructured": "Suttle AB, Hurwitz H, Dowlati A, Fernando N, Savage S, Coviello K, Dar M, Ertel P, Whitehead B, Pandite L (2004) Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Proc Am Soc Clin Oncol abstr 3054"}, {"key": "23_CR138", "doi-asserted-by": "crossref", "first-page": "2768", "DOI": "10.1093/emboj/20.11.2768", "volume": "20", "author": "T. Takahashi", "year": "2001", "unstructured": "Takahashi T, Yamaguchi S, Chida K, Shibuya M (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20:2768\u20132778", "journal-title": "EMBO J"}, {"key": "23_CR139", "unstructured": "Takeda M, Arao T, Yokote H, Sakai K, Kimura H, Yanagihara K, Sasaki H, Tamura T, Saijo N, Nishio K (2006) AZD2171 shows potent anti-tumor activity against gastric cancer expressing variant K-SAM/FGFR2. Proc Am Assoc Cancer Res 47 abstr 3785"}, {"key": "23_CR140", "doi-asserted-by": "crossref", "first-page": "4162", "DOI": "10.1200/JCO.2005.09.034", "volume": "23", "author": "A.L. Thomas", "year": "2005", "unstructured": "Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23:4162\u20134171", "journal-title": "J Clin Oncol"}, {"key": "23_CR141", "unstructured": "Tolcher AW, O\u2019Leary JJ, DeBono JS, Caulkins JD, Molpus K, Sutula K, Ferrante KJ, Gualberto A, Noe DA, Huberman M, Healey D (2002) A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol abstr 334"}, {"key": "23_CR142", "doi-asserted-by": "crossref", "first-page": "4931", "DOI": "10.1158/0008-5472.CAN-03-3681", "volume": "64", "author": "P. Traxler", "year": "2004", "unstructured": "Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G (2004) AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64:4931\u20134941", "journal-title": "Cancer Res"}, {"key": "23_CR143", "doi-asserted-by": "crossref", "first-page": "1381", "DOI": "10.1016/S0002-9440(10)65392-8", "volume": "154", "author": "R. Valtola", "year": "1999", "unstructured": "Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K (1999) VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154:1381\u20131390", "journal-title": "Am J Pathol"}, {"key": "23_CR144", "first-page": "26988", "volume": "269", "author": "J. Waltenberger", "year": "1994", "unstructured": "Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988\u201326995", "journal-title": "J Biol Chem"}, {"key": "23_CR145", "first-page": "970", "volume": "60", "author": "S.R. Wedge", "year": "2000", "unstructured": "Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF (2000) ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broadspectrum antitumor efficacy. Cancer Res 60:970\u2013975", "journal-title": "Cancer Res"}, {"key": "23_CR146", "first-page": "4645", "volume": "62", "author": "S.R. Wedge", "year": "2002", "unstructured": "Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645\u20134655", "journal-title": "Cancer Res"}, {"key": "23_CR147", "doi-asserted-by": "crossref", "first-page": "52", "DOI": "10.1016/S1359-6349(04)80173-3", "volume": "2", "author": "S Wedge", "year": "2004", "unstructured": "Wedge S, Kendrew J, Valentine PJ, Brave SR, Barnett S, J\u00fcrgensmeier JM, Hennequin LF, Oglivie DJ (2004) AZD2171, a potent VEGF receptor tyrosine kinase inhibitor, combined with mechanistically distinct antitumor therapies in vivo. EJC Suppl 2:52", "journal-title": "EJC Suppl"}, {"key": "23_CR148", "doi-asserted-by": "crossref", "first-page": "4389", "DOI": "10.1158/0008-5472.CAN-04-4409", "volume": "65", "author": "S.R. Wedge", "year": "2005", "unstructured": "Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, J\u00fcrgensmeier JM, Ogilvie DJ (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389\u20134400", "journal-title": "Cancer Res"}, {"key": "23_CR149", "unstructured": "Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, Morse M, Burch W, Schlumberger M (2006) A Phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Proc Am Soc Clin Oncol abstr 5533"}, {"key": "23_CR150", "unstructured": "Wickman G, Hallin M, Dillon R, Amundson K, Acena A, Grazzini M, Hermann M, Vekich S, McTigue M, Kania R, Bender S, Shalinsky DR, Hu-Lowe DD (2003) Further characterisation of the potent VEGF/PDGT receptor-tyrosine kinase inhibitor, AG013736, in preclinical tumour models for its antiangiogenesis and antitumour activity. Proc Am Assoc Cancer Res abstr 3780"}, {"key": "23_CR151", "doi-asserted-by": "crossref", "first-page": "7099", "DOI": "10.1158/0008-5472.CAN-04-1443", "volume": "64", "author": "S.M. Wilhelm", "year": "2004", "unstructured": "Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109", "journal-title": "Cancer Res"}, {"key": "23_CR152", "first-page": "2178", "volume": "60", "author": "J.M. Wood", "year": "2000", "unstructured": "Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O\u2019Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178\u20132189", "journal-title": "Cancer Res"}, {"key": "23_CR153", "doi-asserted-by": "crossref", "first-page": "241", "DOI": "10.1016/S0163-7258(98)00045-X", "volume": "82", "author": "J.R. Woodburn", "year": "1999", "unstructured": "Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241\u2013250", "journal-title": "Pharmacol Ther"}, {"key": "23_CR154", "unstructured": "Wu W, Fujitaka K, Mandai J, Imagumbai T, Ryan A, J\u00fcrgensmeier JM, Fidler IJ, O\u2019Reilly MS, Herbst RS (2005) AZD2171, an oral, highly potent VEGFR signaling inhibitor, in combination with gefitinib or paclitaxel: results of a study in an orthotopic human lung adenocarcinoma model. Clin Cancer Res 11 abstr B7"}, {"key": "23_CR155", "first-page": "501", "volume": "79", "author": "S. Yamagishi", "year": "1999", "unstructured": "Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, Tanaka N, Yamamoto H (1999) Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 79:501\u2013509", "journal-title": "Lab Invest"}, {"key": "23_CR156", "doi-asserted-by": "crossref", "first-page": "32714", "DOI": "10.1074/jbc.M103130200", "volume": "276", "author": "H. Zeng", "year": "2001", "unstructured": "Zeng H, Sanyal S, Mukhopadhyay D (2001) Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276:32714\u201332719", "journal-title": "J Biol Chem"}, {"key": "23_CR157", "doi-asserted-by": "crossref", "first-page": "3225", "DOI": "10.3748/wjg.v10.i21.3225", "volume": "10", "author": "Y.J. Zhou", "year": "2004", "unstructured": "Zhou YJ, Xiong YX, Wu XT, Shi D, Fan W, Zhou T, Li YC, Huang X (2004) Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol 10:3225\u20133229", "journal-title": "World J Gastroenterol"}, {"key": "23_CR158", "doi-asserted-by": "crossref", "first-page": "2496", "DOI": "10.1210/endo.143.7.8896", "volume": "143", "author": "R.C. Zimmermann", "year": "2002", "unstructured": "Zimmermann RC, Xiao E, Bohlen P, Ferin M (2002) Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. Endocrinology 143:2496\u20132502", "journal-title": "Endocrinology"}], "container-title": ["Tumor Angiogenesis"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-540-33177-3_23", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 5]], "date-time": "2019-05-05T13:52:34Z", "timestamp": 1557064354000}, "score": 43.347763, "issued": {"date-parts": [[null]]}, "ISBN": ["9783540331766"], "references-count": 158, "URL": "http://dx.doi.org/10.1007/978-3-540-33177-3_23", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:37:38Z", "timestamp": 1574113058056}, "reference-count": 28, "publisher": "Springer Science and Business Media LLC", "issue": "7", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2002, 4, 1]], "date-time": "2002-04-01T00:00:00Z", "timestamp": 1017619200000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Br J Cancer"], "published-print": {"date-parts": [[2002, 4]]}, "DOI": "10.1038/sj.bjc.6600182", "type": "journal-article", "created": {"date-parts": [[2002, 9, 5]], "date-time": "2002-09-05T18:16:41Z", "timestamp": 1031249801000}, "page": "1157-1161", "source": "Crossref", "is-referenced-by-count": 111, "title": ["ZD1839 (\u2018Iressa\u2019), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model"], "prefix": "10.1038", "volume": "86", "author": [{"given": "K J", "family": "Williams", "sequence": "first", "affiliation": []}, {"given": "B A", "family": "Telfer", "sequence": "additional", "affiliation": []}, {"given": "I J", "family": "Stratford", "sequence": "additional", "affiliation": []}, {"given": "S R", "family": "Wedge", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2002, 4, 2]]}, "reference": [{"key": "BF6600182_CR1", "first-page": "2884", "volume": "5", "author": "T Akimoto", "year": "1999", "unstructured": "Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884\u20132890", "journal-title": "Clin Cancer Res"}, {"key": "BF6600182_CR2", "first-page": "686", "volume": "19", "author": "J Baselga", "year": "2000", "unstructured": "Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A-M, Kaye SB, Kieback DG, Harris A, Ochs J (2000) Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: evidence of good tolerability. Proc Am Soc Clin Oncol 19: 177a 686", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "BF6600182_CR3", "first-page": "4343", "volume": "6", "author": "C Bianco", "year": "2000", "unstructured": "Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placeido S, Bianco AR, Ciardiello F (2000) Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6: 4343\u20134350", "journal-title": "Clin Cancer Res"}, {"key": "BF6600182_CR4", "doi-asserted-by": "publisher", "first-page": "269", "DOI": "10.1093/oxfordjournals.annonc.a058806", "volume": "5", "author": "M Caraglia", "year": "1994", "unstructured": "Caraglia M, Pinto A, Correale P, Zagonel V, Genua G, Leardi A, Pepe S, Bianco AR, Tagliaferri P (1994) 5-Aza-2\u2032-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann Oncol 5: 269\u2013276", "journal-title": "Ann Oncol"}, {"key": "BF6600182_CR5", "first-page": "943", "volume": "47", "author": "J Carmichael", "year": "1987", "unstructured": "Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47: 943\u2013946", "journal-title": "Cancer Res"}, {"issue": "Suppl 1", "key": "BF6600182_CR6", "doi-asserted-by": "publisher", "first-page": "25", "DOI": "10.2165/00003495-200060001-00003", "volume": "60", "author": "F Ciardiello", "year": "2000", "unstructured": "Ciardiello F (2000a) Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 (Suppl 1): 25\u201332, discussion 41\u201342", "journal-title": "Drugs"}, {"key": "BF6600182_CR7", "first-page": "2053", "volume": "6", "author": "F Ciardiello", "year": "2000", "unstructured": "Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000b) Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053\u20132063", "journal-title": "Clin Cancer Res"}, {"key": "BF6600182_CR8", "first-page": "405", "volume": "5", "author": "JN Contessa", "year": "1999", "unstructured": "Contessa JN, Reardon DB, Todd D, Dent P, Mikkelsen RB, Valerie K, Bowers GD, Schmidt-Ullrich RK (1999) The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res 5: 405\u2013411", "journal-title": "Clin Cancer Res"}, {"key": "BF6600182_CR9", "doi-asserted-by": "publisher", "first-page": "2493", "DOI": "10.1091/mbc.10.8.2493", "volume": "10", "author": "P Dent", "year": "1999", "unstructured": "Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich RK (1999) Radiation-induced release of transforming growth factor activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493\u20132506", "journal-title": "Mol Biol Cell"}, {"key": "BF6600182_CR10", "author": "VT DeVita", "year": "1997", "unstructured": "DeVita VT, Hellman S, Rosenberg SA (eds) (1997) Cancer: Principles and practice of oncology 5th edn,New York: Lippincott-Raven", "volume-title": "Cancer: Principles and practice of oncology"}, {"key": "BF6600182_CR11", "first-page": "4613", "volume": "18", "author": "M Dong", "year": "1998", "unstructured": "Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT (1998) Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 18: 4613\u20134619", "journal-title": "Anticancer Res"}, {"key": "BF6600182_CR12", "unstructured": "Ferry D, Hammond L, Ranson M, Kris MG, Miller V, Murray P, Tullo A, Feyereislova A, Averbuch S, Rowinsky E (2000) Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a Phase I study. Proc Am Soc Clin Oncol 19: 5E (3a)"}, {"key": "BF6600182_CR13", "doi-asserted-by": "publisher", "first-page": "1253", "DOI": "10.1038/bjc.1996.525", "volume": "74", "author": "M Maurizi", "year": "1996", "unstructured": "Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Pancini P, Paludetti G, Scambia G, Mancuso S (1996) Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253\u20131257", "journal-title": "Br J Cancer"}, {"key": "BF6600182_CR14", "first-page": "2703", "volume": "3", "author": "J Mendelsohn", "year": "1997", "unstructured": "Mendelsohn J (1997) Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703\u20132707", "journal-title": "Clin Cancer Res"}, {"key": "BF6600182_CR15", "first-page": "107", "volume": "59", "author": "L Milas", "year": "1999", "unstructured": "Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W (1999) Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59: 107\u2013114", "journal-title": "Cancer Res"}, {"key": "BF6600182_CR16", "first-page": "701", "volume": "6", "author": "L Milas", "year": "2000", "unstructured": "Milas L, Mason K, Hunter N, Peterson S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumour radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701\u2013708", "journal-title": "Clin Cancer Res"}, {"key": "BF6600182_CR17", "doi-asserted-by": "publisher", "first-page": "4756", "DOI": "10.1038/sj.onc.1202849", "volume": "18", "author": "DB Reardon", "year": "1999", "unstructured": "Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK (1999) Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 18: 4756\u20134766", "journal-title": "Oncogene"}, {"key": "BF6600182_CR18", "first-page": "1398", "volume": "1", "author": "JR Sainsbury", "year": "1987", "unstructured": "Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987) Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398\u20131402", "journal-title": "Lancet"}, {"key": "BF6600182_CR19", "doi-asserted-by": "publisher", "first-page": "451", "DOI": "10.1089/cbr.1999.14.451", "volume": "14", "author": "MN Saleh", "year": "1999", "unstructured": "Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ (1999) Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14: 451\u2013463", "journal-title": "Cancer Biother Radiopharm"}, {"key": "BF6600182_CR20", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1016/1040-8428(94)00144-I", "volume": "19", "author": "DS Salomon", "year": "1995", "unstructured": "Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183\u2013232", "journal-title": "Crit Rev Oncol Hematol"}, {"key": "BF6600182_CR21", "doi-asserted-by": "publisher", "first-page": "1191", "DOI": "10.1038/sj.onc.1201275", "volume": "15", "author": "RK Schmidt-Ullrich", "year": "1997", "unstructured": "Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB (1997) Radiation-induced proliferation of human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15: 1191\u20131197", "journal-title": "Oncogene"}, {"key": "BF6600182_CR22", "doi-asserted-by": "publisher", "first-page": "795", "DOI": "10.1038/bjc.1977.121", "volume": "35", "author": "PW Sheldon", "year": "1977", "unstructured": "Sheldon PW, Hill SA (1977) Hypoxic cell radiosensitisation and local control by x-ray of a transplanted tumour in mice. Br J Cancer 35: 795\u2013808", "journal-title": "Br J Cancer"}, {"key": "BF6600182_CR23", "first-page": "4885", "volume": "6", "author": "FM Sirotnak", "year": "2000", "unstructured": "Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD1839 (Iressa) an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885\u20134892", "journal-title": "Clin Cancer Res"}, {"key": "BF6600182_CR24", "doi-asserted-by": "publisher", "first-page": "885", "DOI": "10.3109/10799899909038430", "volume": "19", "author": "DG Todd", "year": "1999", "unstructured": "Todd DG, Mikkleson RB, Rorrer WK, Valerie K, Schmidt-Ullrich RK (1999) Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells. J Recept Signal Transduct Res 19: 885\u2013908", "journal-title": "J Recept Signal Transduct Res"}, {"key": "BF6600182_CR25", "doi-asserted-by": "publisher", "first-page": "241", "DOI": "10.1016/S0163-7258(98)00045-X", "volume": "82", "author": "JR Woodburn", "year": "1999", "unstructured": "Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241\u2013250", "journal-title": "Pharmacol Ther"}, {"key": "BF6600182_CR26", "first-page": "1", "volume": "77", "author": "P Workman", "year": "1998", "unstructured": "Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia 2nd edn. Br J Cancer 77: 1\u201310", "journal-title": "Br J Cancer"}, {"key": "BF6600182_CR27", "doi-asserted-by": "publisher", "first-page": "1122", "DOI": "10.1002/(SICI)1097-0142(20000301)88:5<1122::AID-CNCR24>3.0.CO;2-Q", "volume": "88", "author": "Y Yan", "year": "2000", "unstructured": "Yan Y, Carvalhal GF, Catalona WJ, Young JD (2000) Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 88: 1122\u20131130", "journal-title": "Cancer"}, {"key": "BF6600182_CR28", "first-page": "1236", "volume": "59", "author": "XD Yang", "year": "1999", "unstructured": "Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A (1999) Eradication of established tumours by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236\u20131243", "journal-title": "Cancer Res"}], "container-title": ["British Journal of Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/6600182.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/6600182", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/6600182.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 17]], "date-time": "2019-03-17T07:50:23Z", "timestamp": 1552809023000}, "score": 42.832474, "issued": {"date-parts": [[2002, 4]]}, "references-count": 28, "journal-issue": {"published-print": {"date-parts": [[2002, 4]]}, "issue": "7"}, "alternative-id": ["BF6600182"], "URL": "http://dx.doi.org/10.1038/sj.bjc.6600182", "relation": {"cites": []}, "ISSN": ["0007-0920", "1532-1827"], "issn-type": [{"value": "0007-0920", "type": "print"}, {"value": "1532-1827", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T17:59:09Z", "timestamp": 1574186349066}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "19", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2005, 10, 1]]}, "DOI": "10.1158/1078-0432.ccr-05-0720", "type": "journal-article", "created": {"date-parts": [[2006, 3, 21]], "date-time": "2006-03-21T18:43:43Z", "timestamp": 1142966623000}, "page": "6908-6915", "source": "Crossref", "is-referenced-by-count": 30, "title": ["Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies"], "prefix": "10.1158", "volume": "11", "author": [{"given": "R.", "family": "Hoekstra", "sequence": "first", "affiliation": []}], "member": "1086", "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-05-0720", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T04:48:15Z", "timestamp": 1482468495000}, "score": 41.410435, "issued": {"date-parts": [[2005, 10, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2005, 10, 1]]}, "issue": "19"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-05-0720", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T22:29:38Z", "timestamp": 1575152978720}, "reference-count": 65, "publisher": "Springer Science and Business Media LLC", "issue": "S1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 6, 1]], "date-time": "2005-06-01T00:00:00Z", "timestamp": 1117584000000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Br J Cancer"], "published-print": {"date-parts": [[2005, 6]]}, "DOI": "10.1038/sj.bjc.6602603", "type": "journal-article", "created": {"date-parts": [[2005, 5, 31]], "date-time": "2005-05-31T12:21:40Z", "timestamp": 1117542100000}, "page": "S6-S13", "source": "Crossref", "is-referenced-by-count": 106, "title": ["ZD6474 \u2013 a novel inhibitor of VEGFR and EGFR tyrosine kinase activity"], "prefix": "10.1038", "volume": "92", "author": [{"given": "A J", "family": "Ryan", "sequence": "first", "affiliation": []}, {"given": "S R", "family": "Wedge", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 6, 3]]}, "reference": [{"key": "BF6602603_CR1", "doi-asserted-by": "publisher", "first-page": "9101", "DOI": "10.1158/0008-5472.CAN-04-2360", "volume": "64", "author": "T Arao", "year": "2004", "unstructured": "Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K (2004) Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64: 9101\u20139104", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR2", "doi-asserted-by": "publisher", "first-page": "184", "DOI": "10.1002/ijc.20211", "volume": "111", "author": "H Bando", "year": "2004", "unstructured": "Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, Sipos B, Grone HJ, Weich HA (2004) Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int J Cancer 111: 184\u2013191", "journal-title": "Int J Cancer"}, {"key": "BF6602603_CR3", "doi-asserted-by": "publisher", "first-page": "159", "DOI": "10.1172/JCI5028", "volume": "103", "author": "LE Benjamin", "year": "1999", "unstructured": "Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159\u2013165", "journal-title": "J Clin Invest"}, {"key": "BF6602603_CR4", "first-page": "1051", "volume": "45", "author": "DP Bradley", "year": "2004", "unstructured": "Bradley DP, Tessier JT, Checkley DR, Kuribayashi H, Wedge SR (2004) The VEGF signaling inhibitors ZD6474 and AZD2171 compromise hemodynamic parameters in an SW620 human colon tumor model: an analysis using perfusion-permeability dynamic contrast-enhanced magnetic resonance imaging (pp-DCE-MRI). Proc Am Assoc Cancer Res 45: 1051", "journal-title": "Proc Am Assoc Cancer Res"}, {"key": "BF6602603_CR5", "first-page": "1255", "volume": "143", "author": "LF Brown", "year": "1993", "unstructured": "Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993a) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255\u20131262", "journal-title": "Am J Pathol"}, {"key": "BF6602603_CR6", "first-page": "4727", "volume": "53", "author": "LF Brown", "year": "1993", "unstructured": "Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF (1993b) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727\u20134735", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR7", "first-page": "604", "volume": "44", "author": "CJ Bruns", "year": "2003", "unstructured": "Bruns CJ, Kohl G, Guba M, Yezhelyev M, Wiegand U, Ryan A, Barge A, Geissler E, Jauch K-W (2003) Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Proc Am Assoc Cancer Res (2nd Edn) 44: 604", "journal-title": "Proc Am Assoc Cancer Res (2nd Edn)"}, {"key": "BF6602603_CR8", "doi-asserted-by": "publisher", "first-page": "101", "DOI": "10.1002/ijc.10681", "volume": "102", "author": "CJ Bruns", "year": "2002", "unstructured": "Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R, Ellis LM (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102: 101\u2013108", "journal-title": "Int J Cancer"}, {"key": "BF6602603_CR9", "first-page": "2926", "volume": "60", "author": "CJ Bruns", "year": "2000", "unstructured": "Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926\u20132935", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR10", "doi-asserted-by": "publisher", "first-page": "6056", "DOI": "10.1038/sj.onc.1207810", "volume": "36", "author": "F Carlomagno", "year": "2004", "unstructured": "Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M (2004) Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 36: 6056\u20136063", "journal-title": "Oncogene"}, {"key": "BF6602603_CR11", "first-page": "7284", "volume": "62", "author": "F Carlomagno", "year": "2002", "unstructured": "Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284\u20137290", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR12", "doi-asserted-by": "publisher", "first-page": "1889", "DOI": "10.1038/sj.bjc.6601386", "volume": "89", "author": "D Checkley", "year": "2003", "unstructured": "Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR (2003) Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89: 1889\u20131895", "journal-title": "Br J Cancer"}, {"key": "BF6602603_CR13", "doi-asserted-by": "publisher", "first-page": "784", "DOI": "10.1158/1078-0432.CCR-1100-03", "volume": "10", "author": "F Ciardiello", "year": "2004", "unstructured": "Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784\u2013793", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR14", "first-page": "1546", "volume": "9", "author": "F Ciardiello", "year": "2003", "unstructured": "Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546\u20131556", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR15", "first-page": "2958", "volume": "7", "author": "F Ciardiello", "year": "2001", "unstructured": "Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958\u20132970", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR16", "unstructured": "Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Esser N (2005) The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis, in press"}, {"key": "BF6602603_CR17", "first-page": "1029", "volume": "146", "author": "HF Dvorak", "year": "1995", "unstructured": "Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029\u20131039", "journal-title": "Am J Pathol"}, {"issue": "Suppl 1", "key": "BF6602603_CR18", "doi-asserted-by": "publisher", "first-page": "2", "DOI": "10.1634/theoncologist.9-suppl_1-2", "volume": "9", "author": "N Ferrara", "year": "2004", "unstructured": "Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl 1): 2\u201310", "journal-title": "Oncologist"}, {"key": "BF6602603_CR19", "doi-asserted-by": "publisher", "first-page": "669", "DOI": "10.1038/nm0603-669", "volume": "9", "author": "N Ferrara", "year": "2003", "unstructured": "Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669\u2013676", "journal-title": "Nat Med"}, {"key": "BF6602603_CR20", "doi-asserted-by": "publisher", "first-page": "15", "DOI": "10.1053/sonc.2002.37263", "volume": "29", "author": "J Folkman", "year": "2002", "unstructured": "Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15\u201318", "journal-title": "Semin Oncol"}, {"key": "BF6602603_CR21", "doi-asserted-by": "publisher", "first-page": "30336", "DOI": "10.1074/jbc.273.46.30336", "volume": "273", "author": "HP Gerber", "year": "1998", "unstructured": "Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336\u201330343", "journal-title": "J Biol Chem"}, {"key": "BF6602603_CR22", "doi-asserted-by": "publisher", "first-page": "750", "DOI": "10.1093/emboj/16.4.750", "volume": "16", "author": "J Gille", "year": "1997", "unstructured": "Gille J, Swerlick RA, Caughman SW (1997) Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 16: 750\u2013759", "journal-title": "EMBO J"}, {"key": "BF6602603_CR23", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1091/mbc.4.1.121", "volume": "4", "author": "CK Goldman", "year": "1993", "unstructured": "Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121\u2013133", "journal-title": "Mol Biol Cell"}, {"key": "BF6602603_CR24", "first-page": "3374", "volume": "59", "author": "DH Gorski", "year": "1999", "unstructured": "Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR (1999) Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374\u20133378", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR25", "doi-asserted-by": "publisher", "first-page": "989", "DOI": "10.1038/labinvest.3700128", "volume": "84", "author": "SC Heffelfinger", "year": "2004", "unstructured": "Heffelfinger SC, Yan M, Gear RB, Schneider J, LaDow K, Warshawsky D (2004) Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation. Lab Invest 84: 989\u2013998", "journal-title": "Lab Invest"}, {"key": "BF6602603_CR26", "doi-asserted-by": "publisher", "first-page": "1300", "DOI": "10.1021/jm011022e", "volume": "45", "author": "LF Hennequin", "year": "2002", "unstructured": "Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45: 1300\u20131312", "journal-title": "J Med Chem"}, {"key": "BF6602603_CR27", "first-page": "955", "volume": "45", "author": "T Hoang", "year": "2004", "unstructured": "Hoang T, Huang SM, Armstrong EA, Harari PM (2004) Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474. Proc Am Assoc Cancer Res 45: 955", "journal-title": "Proc Am Assoc Cancer Res"}, {"key": "BF6602603_CR28", "doi-asserted-by": "publisher", "first-page": "2335", "DOI": "10.1056/NEJMoa032691", "volume": "350", "author": "H Hurwitz", "year": "2004", "unstructured": "Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335\u20132342", "journal-title": "N Engl J Med"}, {"key": "BF6602603_CR29", "doi-asserted-by": "publisher", "first-page": "685", "DOI": "10.1038/nm0603-685", "volume": "9", "author": "RK Jain", "year": "2003", "unstructured": "Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685\u2013693", "journal-title": "Nat Med"}, {"key": "BF6602603_CR30", "doi-asserted-by": "publisher", "first-page": "504", "DOI": "10.1136/jcp.2003.012963", "volume": "57", "author": "AM Jubb", "year": "2004", "unstructured": "Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW, Hillan KJ (2004) Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol 57: 504\u2013512", "journal-title": "J Clin Pathol"}, {"key": "BF6602603_CR31", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1152/physrev.00005.2002", "volume": "82", "author": "L Jussila", "year": "2002", "unstructured": "Jussila L, Alitalo K (2002) Vascular growth factors and lymphangiogenesis. Physiol Rev 82: 673\u2013700", "journal-title": "Physiol Rev"}, {"key": "BF6602603_CR32", "doi-asserted-by": "publisher", "first-page": "8413", "DOI": "10.1158/1078-0432.CCR-04-0379", "volume": "10", "author": "H Kurahara", "year": "2004", "unstructured": "Kurahara H, Takao S, Maemura K, Shinchi H, Natsugoe S, Aikou T (2004) Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10: 8413\u20138420", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR33", "doi-asserted-by": "publisher", "first-page": "403", "DOI": "10.1016/S1471-4892(02)00184-4", "volume": "2", "author": "S Madhusudan", "year": "2002", "unstructured": "Madhusudan S, Harris AL (2002) Drug inhibition of angiogenesis. Curr Opin Pharmacol 2: 403\u2013414", "journal-title": "Curr Opin Pharmacol"}, {"key": "BF6602603_CR34", "doi-asserted-by": "publisher", "first-page": "1715", "DOI": "10.1517/13543784.11.12.1715", "volume": "11", "author": "PW Manley", "year": "2002", "unstructured": "Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM (2002) Therapies directed at vascular endothelial growth factor. Expert Opin Invest Drugs 11: 1715\u20131736", "journal-title": "Expert Opin Invest Drugs"}, {"key": "BF6602603_CR35", "first-page": "1306", "volume": "60", "author": "JL Masferrer", "year": "2000", "unstructured": "Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306\u20131311", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR36", "first-page": "4064", "volume": "6", "author": "R Masunaga", "year": "2000", "unstructured": "Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6: 4064\u20134068", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR37", "first-page": "9", "volume": "44", "author": "Y Matsumori", "year": "2003", "unstructured": "Matsumori Y, Goto H, Nakataki E, Kanematsu T, Yano S, Wedge S, Ryan A, Sone S (2003) ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase activity, inhibits growth of human non-small cell lung cancer metastases that are resistant to treatment with ZD1839. Proc Am Assoc Cancer Res (2nd Edn) 44: 9", "journal-title": "Proc Am Assoc Cancer Res (2nd Edn)"}, {"key": "BF6602603_CR38", "first-page": "RE21", "volume": "2001", "author": "T Matsumoto", "year": "2001", "unstructured": "Matsumoto T, Claesson-Welsh L (2001) VEGF receptor signal transduction. Sci STKE 2001: RE21", "journal-title": "Sci STKE"}, {"key": "BF6602603_CR39", "first-page": "1041", "volume": "3", "author": "MF McCarty", "year": "2004", "unstructured": "McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ, Ellis LM (2004) ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3: 1041\u20131048", "journal-title": "Mol Cancer Ther"}, {"key": "BF6602603_CR40", "unstructured": "Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N (2003) A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 194"}, {"key": "BF6602603_CR41", "doi-asserted-by": "publisher", "first-page": "3955", "DOI": "10.1200/JCO.2003.08.092", "volume": "21", "author": "B Morgan", "year": "2003", "unstructured": "Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield KM, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O'Byrne KJ, Henry A, Cherryman GR, Leurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrokine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J Clin Oncol 21: 3955\u20133964", "journal-title": "J Clin Oncol"}, {"key": "BF6602603_CR42", "doi-asserted-by": "publisher", "first-page": "1800", "DOI": "10.1126/science.1095920", "volume": "303", "author": "ME Noble", "year": "2004", "unstructured": "Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800\u20131805", "journal-title": "Science"}, {"key": "BF6602603_CR43", "first-page": "257", "volume": "5", "author": "P Perrotte", "year": "1999", "unstructured": "Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257\u2013265", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR44", "doi-asserted-by": "publisher", "first-page": "520", "DOI": "10.1002/ijc.2910590415", "volume": "59", "author": "KH Plate", "year": "1994", "unstructured": "Plate KH, Breier G, Weich HA, Mennel HD, Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520\u2013529", "journal-title": "Int J Cancer"}, {"key": "BF6602603_CR45", "doi-asserted-by": "publisher", "first-page": "1207", "DOI": "10.1200/JCO.2001.19.4.1207", "volume": "19", "author": "RT Poon", "year": "2001", "unstructured": "Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19: 1207\u20131225", "journal-title": "J Clin Oncol"}, {"key": "BF6602603_CR46", "doi-asserted-by": "publisher", "first-page": "24", "DOI": "10.1046/j.1087-0024.2000.00012.x", "volume": "5", "author": "J Rak", "year": "2000", "unstructured": "Rak J, Yu JL, Klement G, Kerbel RS (2000) Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Invest Dermatol Symp Proc 5: 24\u201333", "journal-title": "J Invest Dermatol Symp Proc"}, {"key": "BF6602603_CR47", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1016/1040-8428(94)00144-I", "volume": "19", "author": "DS Salomon", "year": "1995", "unstructured": "Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183\u2013232", "journal-title": "Crit Rev Oncol Hematol"}, {"key": "BF6602603_CR48", "doi-asserted-by": "publisher", "first-page": "116", "DOI": "10.1111/j.1749-6632.2002.tb04102.x", "volume": "963", "author": "M Santoro", "year": "2002", "unstructured": "Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G (2002) Molecular mechanisms of RET activation in human cancer. Ann NY Acad Sci 963: 116\u2013121", "journal-title": "Ann NY Acad Sci"}, {"key": "BF6602603_CR49", "doi-asserted-by": "publisher", "first-page": "789", "DOI": "10.1002/cncr.11583", "volume": "98", "author": "C Schietroma", "year": "2003", "unstructured": "Schietroma C, Cianfarani F, Lacal PM, Odorisio T, Orecchia A, Kanitakis J, D'Atri S, Failla CM, Zambruno G (2003) Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 98: 789\u2013797", "journal-title": "Cancer"}, {"key": "BF6602603_CR50", "doi-asserted-by": "publisher", "first-page": "983", "DOI": "10.1126/science.6823562", "volume": "219", "author": "DR Senger", "year": "1983", "unstructured": "Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983\u2013985", "journal-title": "Science"}, {"key": "BF6602603_CR51", "doi-asserted-by": "publisher", "first-page": "768", "DOI": "10.1073/pnas.92.3.768", "volume": "92", "author": "D Shweiki", "year": "1995", "unstructured": "Shweiki D, Neeman M, Itin A, Keshet E (1995) Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768\u2013772", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BF6602603_CR52", "doi-asserted-by": "publisher", "first-page": "152", "DOI": "10.1111/j.1442-2042.2005.01010.x", "volume": "12", "author": "K Suzuki", "year": "2005", "unstructured": "Suzuki K, Morita T, Tokue A (2005) Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol 12: 152\u2013158", "journal-title": "Int J Urol"}, {"key": "BF6602603_CR53", "doi-asserted-by": "publisher", "first-page": "829", "DOI": "10.1080/028418699432518", "volume": "38", "author": "AG Taghian", "year": "1999", "unstructured": "Taghian AG, Suit HD (1999) Animal systems for translational research in radiation oncology. Acta Oncol 38: 829\u2013838", "journal-title": "Acta Oncol"}, {"key": "BF6602603_CR54", "doi-asserted-by": "publisher", "first-page": "984", "DOI": "10.1111/j.1349-7006.2004.tb03187.x", "volume": "95", "author": "F Taguchi", "year": "2004", "unstructured": "Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K (2004) Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (\u2018Iressa\u2019)-sensitive and resistant xenograft models. Cancer Sci 95: 984\u2013989", "journal-title": "Cancer Sci"}, {"key": "BF6602603_CR55", "first-page": "1268", "volume": "11", "author": "C Tuccillo", "year": "2005", "unstructured": "Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F (2005) Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 11: 1268\u20131276", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR56", "first-page": "6141S", "volume": "9", "author": "HJ Varghese", "year": "2003", "unstructured": "Varghese HJ, MacKenzie LT, Groom AC, Ellis CG, Ryan A, MacDonald IC, Chambers AF (2003) The vascular-targeting agent, ZD6126, and the antiangiogenic agent, ZD6474, inhibit liver metastases via differential effects on metastatic vasculature. Clin Cancer Res 9: 6141S", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR57", "first-page": "2940", "volume": "63", "author": "KL Weber", "year": "2003", "unstructured": "Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ (2003) Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63: 2940\u20132947", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR58", "first-page": "4645", "volume": "62", "author": "SR Wedge", "year": "2002", "unstructured": "Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645\u20134655", "journal-title": "Cancer Res"}, {"key": "BF6602603_CR59", "first-page": "1075", "volume": "45", "author": "RW Wilkinson", "year": "2004", "unstructured": "Wilkinson RW, Ryan AJ, Wedge SR, Pyrah IT, Mandir N, Goodlad RA (2004) The VEGF receptor tyrosine kinase inhibitor ZD6474 significantly reduces intestinal tumor burden in the Min mouse. Proc Am Assoc Cancer Res 45: 1075", "journal-title": "Proc Am Assoc Cancer Res"}, {"key": "BF6602603_CR60", "doi-asserted-by": "publisher", "first-page": "145", "DOI": "10.1038/nm988", "volume": "10", "author": "CG Willett", "year": "2004", "unstructured": "Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145\u2013147", "journal-title": "Nat Med"}, {"key": "BF6602603_CR61", "doi-asserted-by": "publisher", "first-page": "8587", "DOI": "10.1158/1078-0432.CCR-04-1147", "volume": "10", "author": "KJ Williams", "year": "2004", "unstructured": "Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10: 8587\u20138593", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR62", "first-page": "1051", "volume": "45", "author": "W Wu", "year": "2004", "unstructured": "Wu W, Isobe T, Itasaka S, Shintani T, Langley RR, Onn A, Hansen JC, O'Reilly MS, Herbst RS (2004) ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. Proc Am Assoc Cancer Res 45: 1051", "journal-title": "Proc Am Assoc Cancer Res"}, {"key": "BF6602603_CR63", "first-page": "6143S", "volume": "9", "author": "W Wu", "year": "2003", "unstructured": "Wu W, Isobe T, Onn A, Shintani T, Itasaka S, Shibuya K, Langley RR, Hansen JC, Fidler IJ, Ryan A, Herbst RS, O'Reilly MS (2003) Targeted therapy against VEGF and EGF receptor signaling with ZD6474 blocks angiogenesis and inhibits the growth and dissemination of orthotopic human lung cancer in mice. Clin Cancer Res 9: 6143S", "journal-title": "Clin Cancer Res"}, {"key": "BF6602603_CR64", "doi-asserted-by": "publisher", "first-page": "242", "DOI": "10.1038/35025215", "volume": "407", "author": "GD Yancopoulos", "year": "2000", "unstructured": "Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407: 242\u2013248", "journal-title": "Nature"}, {"key": "BF6602603_CR65", "doi-asserted-by": "publisher", "first-page": "5137", "DOI": "10.1158/1078-0432.CCR-03-0434", "volume": "10", "author": "Y Zeng", "year": "2004", "unstructured": "Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, Stacker SA, Sutherland RL, Williams ED (2004) Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 10: 5137\u20135144", "journal-title": "Clin Cancer Res"}], "container-title": ["British Journal of Cancer"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/6602603.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/6602603", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/6602603.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 16]], "date-time": "2019-03-16T10:49:40Z", "timestamp": 1552733380000}, "score": 41.17997, "issued": {"date-parts": [[2005, 6]]}, "references-count": 65, "journal-issue": {"published-print": {"date-parts": [[2005, 6]]}, "issue": "S1"}, "alternative-id": ["BF6602603"], "URL": "http://dx.doi.org/10.1038/sj.bjc.6602603", "relation": {"cites": []}, "ISSN": ["0007-0920", "1532-1827"], "issn-type": [{"value": "0007-0920", "type": "print"}, {"value": "1532-1827", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}